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SUMMARY 
                                                                      
 
Meisoindigo has been a routine therapeutic agent in the clinical treatment of chronic 
myelogenous leukemia in China since the 1980s. However, information relevant to 
the metabolism of meisoindigo is limited.  
In this thesis, in vitro metabolism studies were firstly carried out in rat, pig and human 
liver microsomes of different genders by LC-MS/MS. The qualitative metabolite 
identification was accomplished by integration of MRM with conventional full MS 
scan followed by MS/MS methodology, together with chiral chromatography, proton 
NMR spectroscopy and synchrotron infrared spectroscopy. The semi-quantitative 
metabolic stability and metabolite formation were simultaneously measured by MRM. 
The in vitro metabolic pathways of meisoindigo in three species were proposed as 
stereoselective 3,3’ double bond reduction, stereoselective reduction followed by 
N-demethylation, both stereoselective and regioselective reduction followed by 
phenyl mono-oxidation, and regioselective phenyl mono-oxidation. Besides, 
N-demethylation was another in vitro metabolic pathway in only pig and human. In 
particular, two metabolites undergone reduction followed by phenyl mono-oxidation 
at positions 4, 5, 6 or 7, as well as one metabolite undergone phenyl mono-oxidation 
were found to be uniquely present in human. The in vitro t1/2 and in vitro CLint values 
of meisoindigo were calculated. Statistical analysis showed there were no significant 
 vi
differences in the metabolic stability profiles of meisoindigo among three species, and 
gender effect on the metabolic stability of meisoindigo was negligible. Formation 
profiles of the most significant reductive metabolites were obtained in the three 
species.  
Secondly, in vitro extrahepatic metabolism of meisoindigo in rat kidney microsomes 
was qualitatively and quantitatively investigated by LC-MS/MS. The major metabolic 
pathways in rat kidney microsomes were proposed as 3,3’ double bond reduction, 
whereas the minor metabolic pathway was phenyl mono-oxidation. The in vitro 
half-life (t1/2) values of meisoindigo in male and female rat kidney microsomes were 
calculated, respectively. There were no statistically significant gender differences in 
the metabolic stability profiles of meisoindigo. The reductive metabolite formation 
profiles of meisoindigo in male and female rat kidney microsomes were plotted 
semi-quantitatively.  
Thirdly, in vivo circulatory metabolites of meisoindigo in male rat plasma, as well as 
excretory metabolites in male rat urine and feces were identified by LC-MS/MS. The 
major metabolic pathway in rat plasma was proposed as 3,3’ double bond reduction, 
whereas the minor metabolic pathways were reduction followed by N-demethylation, 
and reduction followed by phenyl mono-oxidation. The major metabolic pathways in 
the rat urine were proposed as reduction followed by phenyl mono-oxidation, and its 
glucuronide conjugation and sulfate conjugation, whereas the minor metabolic 
pathways were 3,3’ double bond reduction, N-demethylation, reduction followed by 
N-demethylation, phenyl di-oxidation, phenyl mono-oxidation and its glucuronide 
 vii
conjugation and sulfate conjugation. The major metabolic pathway in the rat feces 
was proposed as reduction followed by phenyl mono-oxidation, whereas the minor 
metabolic pathways were reduction followed by N-demethylation, and reduction 
followed by phenyl di-oxidation. The phase I metabolic pathways showed a 
significant in vitro-in vivo correlation in rat. 
This study shed new light in the metabolic profiles of meisoindigo in rat, pig and 
human. The findings may allow clinicians and researchers better understanding on the 
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CHAPTER 1 
Introduction 
                                                                      
Drug metabolism, namely biotransformation, is a biochemical process in which the 
drug is converted into hydrophilic metabolites and subsequently the excretion of this 
drug in the form of metabolites from the body is facilitated. In most cases, drug 
metabolism leads to the inactivation of drugs. But sometimes it also leads to the 
generation of active metabolites, which can be solely or partially responsible for the 
pharmacological response, or even reactive intermediates and toxic metabolites with 
potential toxicological implications. Therefore, a good understanding of the metabolic 
profiles of drugs in animals and humans plays a critical role in drug discovery and 
development (Kumar and Surapaneni, 2001). However, the metabolic profiles of few 
drugs in the clinical application have not yet been explored in depth so far. One of the 
examples is meisoindigo, an anti-leukemic agent. Its metabolic profile was almost 
absent in the literatures and therefore, the in vitro and in vivo metabolism of 
meisoindigo were evaluated in this thesis. Before introducing the background of 
meisoindigo in section 1.2, the fundamental knowledge, relevant approaches and 
technologies regarding drug metabolism will be first described briefly in the 
following section. 
 1
1.1 FUNDAMENTALS OF DRUG METABOLISM 
In general, drug metabolism in mammals involves two types of transformations: they 
are phase I reactions (functionalization) and phase II reactions (conjugation). Phase I 
reactions include oxidation, reduction and hydrolysis that increase the polarity and 
also the excretion of the drug (Gibson and Skett, 1994). Typically oxidation reactions, 
the main phase I reactions, are catalyzed by cytochrome P450 (CYP450), flavin 
monooxidase (FMO) or monoamine oxidase (MAO). Reduction reactions are 
catalyzed by various reductases or hydrogenases. Hydrolysis reactions are catalyzed 
by diverse esterases or amidases. In most cases, phase I reactions are preparative 
stages for the subsequent phase II reactions. The main phase II reaction is 
glucuronidation in all mammals. The other important reactions involve sulfation, 
methylation, acetylation and conjugation with amino acid or glutathione (GSH) or 
fatty acid (Gibson and Skett, 1994; Mulder et al., 1990).  
Typically, there are various factors which have a profound influence on drug 
metabolism. They are divided into internal factors and external factors (Gibson and 
Skett, 1994). Internal factors involve species, genetics, age, sex, hormones (e.g. 
pituitary gland, sex glands, adrenal glands, thyroid gland, pancreas and pregnancy), 
and disease (e.g. cirrhosis of the liver, alcoholic liver disease, cholestatic jaundice, 
liver carcinoma, endocrine disorders, infections and inflammation). External factors 
involve diet (e.g. protein, fat, carbohydrates, vitamins, trace elements, pyrolysis 
products, tobacco smoke, and alcohol), and environment (e.g. petroleum products, 
heavy metals, insecticides, herbicides, industrial pollutants, and motor vehicle 
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exhaust). 
Since a majority of drug metabolism occurs in the liver, the current in vitro drug 
metabolism models include metabolizing recombinant enzymes such as CYP450 and 
UDP-glucuronosyltransferases; subcellular fractions such as liver microsomes, 
cytosols or S9 fractions; cellular organelles such as hepatocytes and liver slices (Ekins 
et al., 2000), which vary in their levels of cellular integrity. The primary systems 
commonly used are either liver microsomes or hepatocytes (plated or suspended). 
Liver microsomes are prepared from liver homogenates, with cytochrome P450 
metabolizing enzymes locating within the endoplasmic reticulum. However, 
microsomes do not contain other cytosolic or organelle-associated metabolizing 
enzymes or cytosolic conjugating enzymes, and thus have to be fortified with either 
nicotinamide adenine dinucleotide phosphate (NADPH) or an NADPH-regenerating 
system to function. Rat, rabbit, dog, monkey, pig or minipig liver microsomes are 
typically used animal experimental models of drug metabolism with their own 
characteristics (Zuber et al., 2002). For CYP1A-mediated pathways, all experimental 
models are appropriate except probably the dog, whereas dog seems to be suitable for 
modeling of processes dependent on the CYP2D. Monkey is a good model for 
metabolism mediated by CYP2C, whereas pig or minipig is a good model for CYP3A 
(Zuber et al., 2002). 
Hepatocytes are isolated from the liver tissue by enzymatic dissociation using 
collagenase perfusion (Seglen, 1976; LeCluyse et al., 1996). The primary cells can be 
plated for long-term usage (1 week or more), cyropreserved for future use, or used 
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immediately in suspension (2-6 h). The major advantage of hepatocytes over 
microsomes is that, as a cellular system, hepatocytes contain the full complement of 
drug metabolizing enzymes (phase I and II) and need no supplementation to function 
properly.  
In addition to the liver, a range of other tissues such as kidney, lung, small intestine 
and colon contain drug-metabolizing enzymes and contribute to drug metabolism (De 
Kanter et al., 2004). It was reported that critical drug metabolizing enzymes such as 
cytochrome P450, cysteine conjugateβ-lyase, epoxide hydrolyase, ketone reductase, 
sulfotransferase are present in kidney microsomes (James et al., 1998). Therefore, in 
vitro metabolic preparations, especially microsomes, could be prepared from any 
tissue to study extrahepatic drug metabolism. 
In vivo biological samples such as the urine, plasma, bile and feces are usually 
collected from animals or humans at different time points after administration of a 
certain drug, which could give a more complete picture of both phase I and phase II 
drug metabolism, a first definition of the main elimination routes, as well as an early 
indication of the presence of critical metabolites. However, in vivo drug metabolism 
studies in biological samples generally present more challenges than in vitro studies 
due to the fact that metabolites, often occurring at trace levels, have to be detected and 
identified in the presence of high amounts of salts and endogenous compounds. 
Solid-phase extraction (SPE) and liquid-liquid extraction (LLE) may be applied to in 
vivo biological samples in drug metabolism studies and will inevitably result in 
cleaner samples than cruder approaches, such as protein precipitation, and also 
 4
potentially enable trace-enrichment of low-level drug-related components. The 
disadvantage of more thorough sample clean-up is the increased analysis time. 
Diverse bioanalytical technologies have been applied in the field of drug metabolism, 
such as radioimmunoassay (RIA), gas chromatography coupled with mass 
spectrometry (GC-MS), liquid chromatography (LC) coupled with ultraviolet (UV), 
fluorescence, radioactivity or tandem mass spectrometry (MS/MS). Among these 
technologies, liquid chromatography coupled with tandem mass spectrometry 
(LC-MS/MS) has now become the most powerful tool owing to its superior specificity, 
sensitivity and efficiency (Kostiainen et al., 2003). In some cases, LC-MS/MS has to 
be in association with other techniques, such as chemical derivatization, 
hydrogen/deuterium (H/D) exchange, NMR spectroscopy and stable-isotope labelling 
(Elipe et al., 2003; Hop et al., 2002; Liu and Hop, 2005; Weidolf and Covey, 1992). 
As LC-MS/MS is the main tool for both qualitative and quantitative analysis to 
investigate the meisoindigo metabolism in this thesis, more details of this powerful 
technology are given as follows. 
1.2 LC-MS/MS IN DRUG METABOLISM STUDIES 
For modern LC-MS/MS analysis, electrospray ionization (ESI) and atmospheric 
pressure chemical ionization (APCI) techniques are widely used, which is attributed 
to their efficient ionization for very different type of molecules including polar, labile, 
and high molecular mass drugs and metabolites. The recently introduced method of 
atmospheric pressure photoionization (APPI) has expanded the applicability towards 
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less polar compounds (Robb et al., 2000). In particular, as the softest ionization 
technique, ESI is the most suitable for labile conjugates such as glucuronides and 
sulfates and is therefore preferred in metabolite analysis (Keski-Hynnila et al., 2002).  
There are four basic types of mass spectrometers available for interfacing with LC, 
namely single quadrupole (Q) mass spectrometer, time of flight (TOF) mass 
spectrometer, triple quadrupole (QQQ) mass spectrometer and ion trap (IT) mass 
spectrometer (Korfmacher, 2005). Q provides a mass spectrum for each 
chromatographic peak that elutes from the LC column and is analyzed by the MS 
system. TOF has the capability of providing a higher mass resolution spectrum from 
each component that is assayed. QQQ has a good quantitative capability in the 
multiple reaction monitoring (MRM) scan and the metabolites can easily be identified 
using neutral loss and precursor ion scans. IT has the unique capability of producing 
MSn data that are important when performing structural elucidation assays. 
In the past few years, there are a growing number of hybrid mass spectrometers that 
combine two of the basic types of mass spectrometer to make a specialty system. 
Typical examples are Q-TOF MS/MS (Shevchenko et al., 1997), Q-Trap MS/MS 
(Hopfgartner et al., 2003) and linear ion trap fourier transform mass spectrometer 
(LTQ-FT MS) (Brown et al., 2005). A new chromatographic tool, ultra-high 
performance liquid chromatography (UPLC), has also been available recently. UPLC 
has the capability in higher chromatographic resolution through small particle packing 
column material and high pressure pumps. It is clear that UPLC has a great potential 
for drug metabolism applications (Johnson and Plumb, 2005). 
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For a drug to be effective and safe, the biotransformation should not lead to the 
formation of unwanted active and/or toxic metabolites, or a rapid clearance from the 
body, or unwanted drug-drug interactions. Therefore, phase I and phase II metabolites 
identification, metabolic stability of the parent drug and formation rates of the major 
metabolites, inhibition and induction assays by cytochrome P450 are important 
aspects in drug metabolism studies with the tool of LC-MS/MS. 
A typical procedure for metabolite identification by LC-MS/MS based on the 
molecular masses and fragmentation patterns involves the initial analysis of test and 
control samples over the full mass range (Sinz and Podoll, 2002; Mutlib and Shockor, 
2003). Based on molecular mass changes relative to the parent compound molecular 
weight, extracted ion chromatograms for potential metabolites can be searched out. 
The non-selective nature of full-scan mass spectrometric data acquisition has the 
advantage of ensuring that most ionizable metabolites will generate a mass 
spectrometric response. However, the approach has the significant disadvantage of 
yielding a multitude of interfering data from non-drug-related components, especially 
when complex biological samples are involved. By targeting specific fragment ions, 
the selectivity of precursor ion (PI) and constant neutral loss (CNL) scanning can also 
facilitate the metabolite detection. In particular, phase II metabolites such as 
glucuronides and sulfates can be screened selectively using specific neutral loss 
transitions (e.g., 176 and 80 Da for the respective conjugates) (Liu and Hop, 2005). 
The disadvantage of this approach is the reduced detection sensitivity of PI and CNL. 
Subsequent product ion (MS/MS) data can generate structural information via 
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interpretation of the fragmentation patterns for both metabolite and parent compound. 
MSn data, typically acquired on an ion trap instrument, can supplement product ion 
scanning data via elucidation of additional fragmentation pathways. The MS/MS or 
MSn spectra of the parent compound can be compared with the corresponding spectra 
of the metabolite. Using the known structure of the parent drug and its corresponding 
fragmentation pattern as references, the metabolite structures will then be elucidated. 
The specific fragment ion that shows a shift in its m/z will help to identify the site of 
the modification of the molecule. 
Specific multiple reaction monitoring (MRM) screening is an alternative approach for 
metabolite detection (Mauriala et al., 2005). Utilizing metabolism prediction and 
knowledge of the MS/MS fragmentation of the parent compound, the approach gives 
a significant increase in sensitivity over conventional triple quadrupole screening 
techniques and enables a wide range of potential transitions to be targeted as a result 
of the rapid cycle times. The common biotransformation reactions and their effect on 
molecular formula and molecular weight are summarized in Table 1-1 (Sinz and 








TABLE 1-1. Common biotransformation reactions and their effect on molecular 
formula and molecular weight. 
 
Biotransformation reactions Formula Mass shifts (Da) 
Reduction + H2 + 2 
Methylation + CH2 + 14 
Hydroxylation + O + 16 
Hydrolysis of a ring + H2O + 18 
Acetylation + C2H2O + 42 
Glycine conjugation + C2H3NO + 57 
Sulphate conjugation + SO3 + 80 
Taurine conjugation + C2H5NO2S + 107 
S-Cysteine conjugation + C3H5NO2S + 119 
Glucuronide conjugation + C6H8O6 + 176 
S-Glutathione conjugation + C10H15N3O6S + 305 
Alcohol to ketone - H2 - 2 
Demethylation - CH2 - 14 
Defluorination - F + H - 17 
Dechlorination - Cl + H - 34 
 
Accurate mass data acquired by either TOF or FT instrumentation enables increased 
confidence in the ability to identify metabolites by decreasing the probability of 
interference occurring from non-compound related ion peaks. It is usually used to 
confirm elemental composition of metabolites. Additionally, accurate mass data and 
molecular formulae of fragment ions can be reliably determined, thereby facilitating 
spectral interpretation and structural determination (Nassar and Talaat, 2004). 
There are a few other techniques commonly used for metabolite identification as well. 
Chemical derivatization techniques combined with LC-MS/MS have proven very 
useful for the characterization of novel and unusual metabolites. Derivatization of a 
metabolite results in differentiation from regioisomeric (Hop and Prakash, 2005) or 
isobaric components, increase in molecular weight (Dalvie and O’Donnell, 1998), and 
enhanced ionization efficiency and fragmentation (Anari et al., 2002; Xu et al., 2002). 
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H/D exchange method in conjunction with LC-MS/MS facilitates the estimation of 
the number of labile hydrogen atoms in groups such as –OH, -SH, -NH, -NH2 and 
–COOH, and further the presence or absence of these functional groups (Nassar and 
Talaat, 2004). Using this approach, isomeric monohydroxylated and dihydroxylated 
metabolites can be differentiated from N- or S-oxide formation, and sulfone 
metabolites, respectively (Ohashi et al., 1998; Liu et al., 2001). In addition, H/D 
exchange experiments facilitate structural elucidation and interpretation of MS/MS 
fragmentation processes. NMR is required to characterize the regiochemistry of 
aromatic oxidation, to determine the site of aliphatic oxidation where fragmentation 
pathways are unavailable or inconclusive and to locate functional groups such as OH, 
epoxide and sulfate by comparing NMR spectra of the parent with those of the 
metabolites (Nassar and Talaat, 2004). Labelling of drugs by either stable or 
radioactive labels can be applied to facilitate detection in the complex biological 
matrix and/or structure elucidation (Weidolf and Covey, 1992). 
The main advantages of LC-MS/MS in quantitative analysis of the parent drugs and 
their metabolites are high selectivity and sensitivity that allow the determination of 
analytes at very low concentrations in complex biological matrices. QQQ using single 
(SRM) or multiple reaction monitoring (MRM) is most often used in quantitative 
LC-MS/MS analysis, but IT-MS, TOF and Q-TOF have also been widely and 
increasingly used. Typically the limit of quantitation with LC-MS/MS varies between 
0.01 and 5 ng/ml of drug in a biological sample, which is often sufficient in the 
quantitative analysis of drug metabolites (Gilbert et al., 1995). The background 
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materials in complex biological matrices usually suppress ionization of the analyte in 
ESI (Matuszewski et al., 1998), which may cause significant errors in quantitative 
results. In C18 reversed-phase chromatography early-eluting more hydrophilic 
analytes are more sensitive to suppression than the late-eluting more hydrophobic 
compounds (Bonfiglio et al., 1999). 
Quantitative analysis of the parent drug and its major metabolites can be performed 
simultaneously by MRM scanning in order to evaluate pharmacokinetics of the drug 
involved. In terms of metabolic stability, the depletion method, first-order 
consumption of parent drug is monitored in liver microsomal incubations to yield in 
vitro t1/2 values, assuming that the substrate concentration (1μM) used is well below 
the km value of all the important metabolizing enzymes involved in the drug 
metabolism. The in vitro half-life (t1/2) is measured by the slope of the line resulting 
from plotting the log of the drug peak area versus time, using the following formula 
(Obach et al., 1997; Obach, 1999). 
t1/2 = ln2 / slope 
Subsequently, in vitro intrinsic clearance (Clint), hepatic blood clearance (ClH,b) and 
hepatic extraction ratio (Er) are calculated from the t1/2 value according to the 
following three formulas respectively (Obach et al., 1997; Obach, 1999). 
(i) Clint = (ln2 / t1/2) × (g liver weight / kg body weight) × (ml incubation / mg 
microsomal protein) × (mg microsomal protein / g liver weight) 
(ii) ClH,b = (Q × Clint) / (Q + Clint)  Q is the hepatic blood flow, 20 mL/min/kg 
(iii) Er = ClH,b / Q 
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Extrapolation of in vivo hepatic clearance from in vitro intrinsic clearance involved 
the use of equations describing the well-stirred, parallel tube or dispersion liver 
models of in vivo hepatic clearance (Obach et al., 1997). On the other hand, 
metabolite quantitation is always required when the metabolite is toxic or 
pharmacologically active or when the concentrations of metabolite reach or exceed 
the parent drug concentration in plasma (Sinz and Podoll, 2002). Formation rates of 
the metabolites are calculated under different substrate concentrations when the 
authentic standards are available. Enzyme kinetic assays are performed to calculate 
the apparent Vmax and Km values of the metabolites, according to the 
Michaelis-Menten equation by nonlinear least-squares regression analysis.  
Another crucial aspect in drug metabolism studies is the evaluation of potential 
drug-drug interactions, which can be obtained by studying the in vitro inhibition or 
induction of the metabolism of probe substrates by CYP450 isoenzymes. LC-MS/MS 
is applied to quantitatively monitor the effect of the test compound on the metabolism 
of probe substrates of the CYP450 isoenzymes investigated. Human liver microsomes 
and selective chemical inhibitors could be preferentially employed (Pritchard et al., 
2003). 
1.3 BACKGROUND OF THE ANTI-LEUKEMIC AGENT - MEISOINDIGO 
Meisoindigo (3-(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)-1,3-dihydro-1-methyl-2H- 
indol-2-one), has been a routine therapeutic agent in the clinical treatment of chronic 
myelogenous leukemia (CML) in China since 1980s (Cooperative Group of Clinical 
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Therapy of Meisoindigo, 1988; Xiao et al., 2000; Xiao et al., 2002). In the following 
three subsections, discovery process, mechanism of action, clinical indications and 
side effects regarding meisoindigo will be reviewed respectively. 
1.3.1 Discovery of meisoindigo 
Meisoindigo was discovered as a synthetic derivative of indirubin, an active 
component of a traditional Chinese medicine recipe.  
In the mid-1960s, based on the therapeutic principle of “purge the hepatic substantial 
fire”, Dang Gui Lu Hui Wan, a pill made of 11 herbal medicines, has been used for 
the treatment of CML in China (Institute of Hematology, Chinese Academy of 
Medical Sciences, 1976). It was found that one ingredient, indigo naturalis (Chinese 
name Qing Dai), a dark blue powder originally extracted from the leaves of 
Baphicacanthus cusia or Indigofera tinctoria etc, is the major effective drug in Dang 
Gui Lu Hui Wan. Phase I and II clinical trials of indigo naturalis revealed very 
encouraging therapeutic effects in the treatment of CML (Leukemia Cooperation 
Group of Chinese Academy of Medical Sciences, 1977). Further investigations 
revealed that the anti-leukemic activity of indigo naturalis was attributed to a minor 
constituent (0.11%), namely indirubin (Chinese name Dian Yuhong), a red 
3,2’-bisindole (Institute of Hematology, Chinese Academy of Medical Sciences, 1979; 
Institute of Hematology, Chinese Academy of Medical Sciences, Chengdu Traditional 
Chinese Medical College and Sichuan Institute of Traditional Medicine, 1978; Zhang, 
1982; Chen and Xie, 1984). 
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Indirubin has been approved for clinical trials against chronic myelogenous leukemia 
(CML) in China since 1979 (Institute of Hematology, Chinese Academy of Medical 
Sciences, 1979). However, indirubin showed poor solubility in water and patients 
treated with indirubin had severe side effects affecting the gastrointestinal tract 
(Cooperative Group of Clinical Therapy of Indirubin, 1980; Zheng et al., 1979). In 
order to produce new agents with a bisindole ring structure showing high efficacy and 
low toxicity, a series of analogues of indirubin were designed and synthesized. 
N-methylisoindigotin, abbreviated as meisoindigo (Chinese name Jia Yidian or Yi 
Dianjia), is a 3,3’-bisindole isomer of indirubin among the analogues. Fig. 1-1 shows 















































FIG. 1-1. Chemical structures of indirubin and meisoindigo. 
 
Meisoindigo showed significant anticancer activities for both Lewis Lung carcinoma 
in mice and Walker carcinosarcoma 256 in rats. It exhibits much stronger activity and 
lower toxicity as compared to its parental compound indirubin in animal models. The 
improved absorption of meisoindigo compared to indirubin may be one of the major 
reasons for the enhancement of anticancer activities (Wu et al., 1984; Wu et al., 1985; 
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Ji and Zhang, 1985; Ji et al., 1985). 
1.3.2 Mechanism of action 
The molecular mechanism of action of meisoindigo is still not well understood up to 
now. 
Previous studies have indicated meisoindigo strongly inhibits DNA biosynthesis in 
cancer cells and inhibits the assembly of microtubules (Ji et al., 1991; Liu et al., 1996). 
Experimental results on the mouse leukemia L1210 cell cycle showed meisoindigo 
induced accumulation of S phase cells. The movement of cells in G2+M phase to G1 
phase may also be blocked to some extent (Ji et al., 1991). The induction of cancer 
cell differentiation associated with decreased c-myb oncogene expression might also 
account for the anticancer action and low toxicity of meisoindigo (Liu et al., 1996). 
Recent studies have shown that c-myb activation is linked to the phosphorylation 
mediated by CDKs. In addition, suppressions of cyclin D and its kinase activity have 
been shown to play a role in the induction of cell differentiation (Steinman, 2002; 
Sharifi and Steinman, 2002; Furukawa, 2002). It is further found that meisoindigo 
inhibits cyclin D mediated CDK 4/6 activity at lower concentrations while 
meisoindigo interferes with both cyclin A and/or B mediated CDK 2 or CDK 1 
activity at higher concentrations (Wang et al., 2003). Another recent study indicated 
that the anti-angiogenesis effect of meisoindigo may contribute to the anti-leukemic 
effect of this drug (Xiao et al., 2006). 
In summary, it seems that growth inhibition and apoptosis of the treated cancer cells 
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might be the major mechanism of action of meisoindigo (Xiao et al., 2002). 
1.3.3 Clinical indications and side effects 
In a phase I clinical trial of meisoindigo for the treatment of CML, a total of 20 newly 
diagnosed CML patients were treated at a dose of 50-200 mg/d, po. It was found that 
the suitable dose was 100-150 mg/d (Xiao et al., 2002). In 1985, 134 patients in first 
chronic phase were treated at a dosage of 75-150 mg/d in the phase II clinical trial of 
meisoindigo for the treatment of CML. The hematological complete response (CR) 
and partial response (PR) rates were 32.1% and 48.5%, respectively (Cooperative 
Group of Clinical Therapy of Meisoindigo, 1988). From March 1994 to July 1995, a 
total of 402 patients entered phase III clinical trial. It was shown that meisoindigo was 
equally efficient for both treated and previously treated CML patients. The CR and 
PR rates were 45.0% and 39.3% for newly diagnosed patients and 35.9% and 41.4% 
for pretreated patients (Cooperative Group of Phase III Clinical Trial on Meisoindigo, 
1997).  
In addition, based on retrospective analysis on the efficiency of different treatments 
for 274 CML patients followed over a period of 5 years, meisoindigo in combination 
with hydroxyurea significantly prolonged median duration of chronic phase and 
median survival, as well as reduced incidence of blast crisis compared with 
meisoindigo or hydroxyurea alone, which strongly indicated that meisoindigo has a 
synergistic effect with hydroxyurea (Liu et al., 2000; Xiao et al., 2000).  
Meisoindigo was generally well tolerated. The most frequent side effects were bone, 
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joint and / or muscle pain of varying degrees when the dosage was more than the 
suitable dose. Approximately 30% of patients had mild nausea and vomiting. These 
symptoms usually disappeared in one or two weeks without any treatment. No 
impairment of cardiac, renal and hepatic functions were found and no patients 
developed severe myelosuppression (Cooperative Group of Clinical Therapy of 
Meisoindigo, 1988; Cooperative Group of Phase III Clinical Trial on Meisoindigo, 
1997; Liu et al., 2000; Xiao et al., 2000). 
1.4 PREVIOUS WORK ON MEISOINDIGO METABOLISM AND ITS 
LIMITATIONS 
In order to improve the understanding of its efficacy and safety characteristics, 
investigation of meisoindigo metabolism in animals or humans plays a critical role. 
Before the discussion of relevant works on meisoindigo metabolism, the previous 
metabolism studies of meisoindigo analogues with the similar bisindole ring structure 
will be reviewed briefly herein first. 
The common three bisindole compounds without any substituents are indirubin, a 
3,2’-bisindole (Fig. 1-1); indigo, a 2,2’-bisindole (Fig. 1-2); and isoindigo, a 
3,3’-bisindole (Fig. 1-2). The chemical structures of indigo and isoindigo are shown 




























FIG. 1-2. Chemical structures of indigo and isoindigo. 
 
In vitro metabolism of indirubin and its derivative, indirubin 3’-oxime in rat liver 
microsomes was investigated by reversed phase high performance liquid 
chromatography (RP-HPLC) with UV detector. It was reported that the disappearance 
of indirubin was limited, and three broadly eluting products of indirubin (λmax at 550 
nm) showed λmax values of 550, 570 and 550 nm, respectively (Guengerich et al., 
2004). Incubation of indirubin 3’-oxime with rat liver microsomes led to the partial 
loss of the parent compound, as well as the appearance of a prominent peak eluted just 
prior to indirubin 3’-oxime with the same λmax at 505 nm and another set of broad 
peaks with complex spectra in the region 465-480 nm (Guengerich et al., 2004). 
Subsequent LC-MS/MS experiments on the potential metabolites were unsuccessful 
due to the issue of sensitivity. 
Indigo (also known as indigotin, Chinese name Dian Lan) was investigated as well 
under the same experimental conditions in that study above. Probably due to the poor 
solubility of indigo, its HPLC profile did not show the presence of any potential 
metabolite peaks with UV spectra in the range of 400-720 nm (Guengerich et al., 
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2004). In vitro metabolism of indigo and its derivatives, i.e. indigocarmine, indigo 
trisulfonate, indigo tetrasulfonate and tetrabromoindigo, in rat liver microsomes was 
investigated in another study. It was reported that all three sulfonated indigo 
derivatives, except indigo and tetrabromoindigo, underwent reductive metabolism to 
the leuco form through the formation of a superoxide radical by transferring one 
electron from the electron donor i.e. NADPH (Kohno et al., 2005). Besides, 
NADPH-cytochrome P450 reductase (P450R) in rat liver microsomes could be the 
enzyme responsible for the initiation of reductive activation of those three sulfonated 
indigo derivatives (Kohno et al., 2005). 
Isoindigo (also known as isoindigotin, Chinese name Yi Dianlan), has the same ring 
structure as meisoindigo. The structural difference between isoindigo and meisoindigo 
only lies in the methyl group at position 1, which is absent within the molecule of 
isoindigo (Fig. 1-2) while present within the molecule of meisoindigo (Fig. 1-1). 
However, to our best knowledge, information relevant to metabolism of isoindigo is 
absent so far. 
With regard to meisoindigo metabolism in animals or humans, few publications 
relevant to this topic have been reported so far. According to the literature survey 
information, only one individual study was highly relevant to meisoindigo 
metabolism (Peng and Wang, 1990). In that study, in vitro phase I metabolism of 
meisoindigo in male rat liver microsomes was investigated by reversed phase high 
performance liquid chromatography (RP-HPLC) with diode array detector (DAD). 
The in vitro microsome incubation of meisoindigo was first carried out at 
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physiological temperature followed by liquid-liquid extraction (LLE). The extract 
obtained was subsequently injected onto a YWG-C18 (ODS) column (150 mm × 4 
mm, 5 um) and eluted with methanol and 0.05% phosphoric acid in a linear gradient 
program. Based on the UV chromatogram comparison of control and sample with 
parallel preparation, it was proposed that ten chromatographic peaks were potential in 
vitro metabolites of meisoindigo. Among them, two major chromatographic peaks 
were purified by preparative thin layer chromatography (TLC) and predicted to be 
monohydroxy metabolites based on preliminary electron impact (EI) MS results. 
That above study provided preliminary information closely related to meisoindigo 
metabolism, particularly in terms of retention time, UV absorbance and UV 
wavelength of the potential in vitro metabolites. However, there are a few limitations 
with regard to its experimental design, which are summarized as follows. Firstly, 
HPLC method cannot provide enough structural information to identify the 
metabolites of meisoindigo, and is not sensitive to screen out all of the minor 
metabolites. Other methods such as LC-MS/MS and NMR are required to further 
confirm the metabolite structures of meisoindigo. Secondly, metabolism studies in 
only rodent animal rat cannot provide enough knowledge to predict the metabolism in 
human or non-rodent animal such as pig, due to interspecies variability as an 
important internal factor affecting drug metabolism. In vitro metabolism in human or 
pig microsomes needs to be investigated. Thirdly, only male metabolic profile was 
investigated due to easier availability. Considering gender effect is a key internal 
factor significantly affecting drug metabolism in general, female metabolic profile for 
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meisoindigo metabolism is also an essential aspect that needs to be explored. Fourthly, 
only qualitative metabolite identification was done and is inadequate to describe the 
whole metabolic profile of meisoindigo. Quantitative metabolic stability and 
metabolite formation of meisoindigo are both vital aspects that need to be investigated. 
Fifthly, only metabolism studies in liver, the major metabolizing organ, were done. 
The extrahepatic metabolism of meisoindigo in other metabolizing organs such as 
kidney needs to be examined. Finally, only in vitro phase I metabolism in liver 
microsomes was investigated. In vivo phase I and II metabolisms in plasma, urine and 
feces need to be explored. 
1.5 RESEARCH OBJECTIVES 
The objectives of this thesis were to: 
1) identify in vitro phase I metabolite structures of meisoindigo in rat, pig and 
human liver microsomes by LC-MS/MS; 
2) determine quantitative metabolic stability and metabolite formation of 
meisoindigo in rat, pig and human liver microsomes by LC-MS/MS; 
3) examine the gender effects on the in vitro metabolism in terms of metabolites 
profiling, metabolic stability and metabolites formation; 
4) study in vitro extrahepatic metabolism of meisoindigo in rat kidney microsomes 
by LC-MS/MS; 
5) characterize in vivo circulatory and excretory metabolites in rat plasma, urine and 
feces by LC-MS/MS. 
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The results of this thesis could lead to a better understanding of the correlation of 
metabolic profile among three different species, i.e. rat, pig and human, as well as the 
correlation between in vitro and in vivo metabolism in the rat. Results of the 
interspecies correlation may contribute to a better prediction of the drug metabolism 
in humans based on metabolism in experimental animals, thus avoiding direct trials 
on humans. Results of in vitro and in vivo correlation may be of importance in 
extrapolating in vivo metabolism from in vitro metabolism with minimal trials on 
living animals. In terms of clinical application, results of meisoindigo metabolism in 
human liver microsomes could provide more useful information with regard to the 
appropriate medication for more effective and safer therapy of chronic myelogenous 
leukemia. 
In this thesis, there is no intention to encompass other experimental animal species, 
such as mouse, rabbit, dog or monkey etc. With the exception of gender difference, 
other factors affecting drug metabolism are beyond of the scope of this thesis. 
Furthermore, due to the difficulty in accessing the plasma, urine and feces from pig 
and human, the focus of in vivo metabolism study is restricted to rat. 
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CHAPTER 2 
Identification of stereoisomeric metabolites of meisoindigo in 
rat liver microsomes by achiral and chiral LC-MS/MS 
                                                                      
2.1 INTRODUCTION 
As is mentioned in section 1.3 of Chapter 1, only one previous study was highly 
relevant to meisoindigo metabolism (Peng and Wang, 1990) and there are a few 
limitations with regard to its experimental design. Besides, there are another two 
severe drawbacks in that study. Firstly, the substrate concentration adopted far 
exceeded the upper limit of the typical concentration range (10-50 μM) in metabolite 
identification experiments (Chen et al., 2007). Hence the results obtained could not be 
used to predict the actual in vivo metabolism of meisoindigo. Secondly, liquid-liquid 
extraction (LLE) performed in that study was likely to cause the metabolites loss 
(Clarke et al. 2001), due to the fact that physicochemical properties of metabolites 
present are unknown in a certain extraction solvent or a mixed extraction solvent 
system. Therefore, in vitro metabolism of meisoindigo in male rat liver microsomes 
still need to be investigated with an appropriate experimental design. 
As described in section 1.1 of Chapter 1, liquid chromatography coupled with tandem 
mass spectrometry (LC-MS/MS) has now become the most powerful tool owing to its 
superior specificity, sensitivity and efficiency (Kostiainen et al., 2003). However, 
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LC-MS/MS alone does not always provide sufficient information for structural 
characterization of metabolites, particularly in the aspects of identifying the exact 
position of oxidation, differentiating isomers, or providing the precise structure of 
unusual and/or unstable metabolites (Prakash et al., 2007). In these cases, other 
analytical technologies such as nuclear magnetic resonance (NMR), infrared (IR) or 
even chiral chromatography analysis have to be utilized to supplement additional 
information. 
In light of these considerations mentioned above, the purpose of the study in Chapter 
2 was to qualitatively identify the in vitro metabolites of meisoindigo in rat liver 
microsomes utilizing online LC-MS/MS and other relevant techniques if necessary. 
2.2 MATERIALS AND METHODS 
2.2.1 Chemicals 
All chemicals were of analytical grade and used without further purification. 
Meisoindigo was provided by Institute of Materia Medica, Chinese Academy of 
Medical Sciences and Peking Union Medical College, Beijing, China. Bradford 
reagent, bovine serum albumin (BSA), β-NADPH, Dimethyl sulfoxide (DMSO), 
ammonium acetate, palladium on carbon (Pd/C) and Deuterochloroform (CDCl3) 
were purchased from Sigma Chemical Co. (St. Louis, Mo, USA). HPLC grade 
methanol and acetonitrile were purchased from Fisher Scientific Co. (Fair Lawn, NY, 
USA). Milli-Q water was obtained from a Millipore water purification system 
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(Billerica, MA, USA) and used to prepare buffer solutions and other aqueous 
solutions.  
2.2.2 Liver microsomal preparation 
Pooled rat liver microsomes were prepared according to the method reported 
previously (Gibson and Skett, 1994). Three male Sprague-Dawley (SD) rats were 
obtained from Animal Holding Unit, National University of Singapore and were 
euthanized with CO2 after a 24-h fasting period. The livers were excised, pooled and 
homogenized with a four-fold volume of 0.25 M sucrose solution to make a 20% 
homogenate. The post-mitochondrial supernatant was obtained by centrifuging the 
liver homogenate at the speed of 12500 g for 15 minutes at 2 oC. Microsomal 
fractions were then prepared by mixing the supernatant with one-tenth volume of 
CaCl2 solution before centrifuging at the speed of 27000 g for 15 minutes at 2 oC. The 
pooled extracted liver microsomes were suspended in 0.1M Tris buffer (PH 7.4) and 
stored at -80 ℃ before use. The microsomal protein contents were determined by 
Bradford assay method, using BSA as the standard protein (Bradford, 1976). 
2.2.3 Liver microsomal incubations 
Meisoindigo stock solution in DMSO was added to 0.1 M Tris buffer (pH 7.4) with 
rat liver microsomes. The mixture was first shaken for 5 min for equilibration in a 
shaking water bath at 37 ℃. The incubation was then initiated by adding β-NADPH 
solution. The final concentrations of meisoindigo, NADPH and the microsomal 
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protein were 50 μM, 1 mM and 1 mg/mL, respectively in a typical incubation mixture 
(1 mL). The percentage of DMSO in the incubation mixture was kept less than 0.2 % 
(v/v). Negative controls were prepared either by substituting microsomal protein 
previously heated to 70-100 ℃ for 10 min or by replacing NAPDH with water. 
Samples were incubated for 60 min and the reaction was terminated with the same 
volume of ice-cold acetonitrile to precipitate proteins. Samples were subsequently 
centrifuged at 14000 rpm for 15 min. The supernatant was taken and analyzed by 
LC-MS/MS. All experiments were carried out in duplicate. 
2.2.4 Achiral LC-MS/MS analysis 
2.2.4.1 HPLC-QTRAP 
Both negative controls and samples were analyzed on a Q TRAP™ 2000 LC-MS/MS 
system from Applied Biosystems / MDS Sciex (Concord, Ontario, Canada) coupled to 
an Agilent 1100 HPLC system (Agilent Technologies, Palo Alto, CA, USA). The 
injection volume was 5 μL. Separations were accomplished on a Agilent hypersil 
ODS column (100 ×2.1 mm, 5 μm) (Agilent Technologies, Palo Alto, CA, USA) with 
a guard cartridge at ambient temperature of about 22 ℃. The mobile phase consisted 
of 10 mM ammonium acetate in water (solvent A) and methanol (solvent B) and was 
delivered at a flow rate of 0.2 mL/min. The linear gradient elution program was as 
follows: 30 % to 100 % B over 12 min, followed by an isocratic hold at 100 % B for 
another 3 min. At 15 min, B was returned to 30 % in 1 min and the column was 
equilibrated for 19 min before the next injection. The total run time was 35 min. 
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During LC-MS/MS analysis, up to 3 min of the initial flow was diverted away from 
the mass spectrometer before evaluation of metabolites. The mass spectrometer was 
operated in the positive ion mode with a TurboIonSpray source. The parameter 
conditions were optimized as follows: curtain gas (CUR), 30 (arbitrary units); ion 
source gas 1 (GS1), 50 (arbitrary units); ion source gas 2 (GS2), 60 (arbitrary units); 
source temperature (TEM), 300 ℃; declustering potential (DP), 26 V; collision 
energy (CE), 35 eV; entrance potential (EP), 4.5 V. Enhanced Q3 Single MS (EMS) 
and Enhanced Product Ion (EPI) were utilized to obtain structural information of the 
metabolites. The MS full scan range was set to m/z 50-350. The mass spectrometer 
and the HPLC system were controlled by Analyst 1.4.1 software from Applied 
Biosystems / MDS Sciex.  
2.2.4.2 UPLC-QTOF 
Accurate mass spectral data for the metabolites were obtained with a Q-TOFTM 
Premier mass spectrometer (Waters Micromass, Manchester, UK) coupled to an 
ACQUITY UPLCTM system (Waters Corporation, Milford, MA, USA). The 
separations were performed on an ACQUITY UPLC BEH C18 column (100 × 2.1 
mm, 1.7 μm). The column was maintained at 40 ℃ and eluted with a mobile phase 
consisting of 0.1 % formic acid in water (solvent A) and 0.1 % formic acid in 
methanol (solvent B) at 0.4 mL/min. The gradient elution program was as follows: 30 
% to 95 % B over 6 min, followed by increasing to 99 % B over 0.1 min. Then B was 
returned to 30 % in 0.1 min and the column was equilibrated for 1.8 min before the 
next injection. The total run time was 8 min. The autosampler chamber was 
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maintained at 10 ℃ and the injection volume was 4 μL. The column eluent was 
directed to the mass spectrometer for analysis. The mass spectrometer was equipped 
with an electrospray ionization source and operated in the positive ionization mode. 
Full-scan spectra were acquired from 50 to 1000 m/z with a scan time of 0.3 s. The 
capillary and cone voltages were 3.0 kV and 25 V, respectively. The source and 
desolvation temperatures were 90 °C and 180 °C, respectively. The desolvation gas 
flow rate was 400 L/h and the cone gas flow rate was 10 L/h. The collision energy 
was set at 4 eV. All analyses were acquired using an independent reference spray via 
the LockSprayTM interference to ensure accuracy and reproducibility. The [M+H]+ ion 
of sulfadimethoxine was employed as the lock mass (m/z 311.0814). The LockSpray 
frequency was set at 15 s. The accurate masses and compositions for the precursor 
ions were calculated using the MassLynx V4.0 software incorporated in the 
instrument. 
2.2.4.3 Search for metabolites 
The total ion chromatograms (TIC) of controls and samples for the EMS were first 
compared. The search for structure-related metabolites of meisoindigo was performed 
manually by interpretation of mass spectra and chromatograms. The possible 
molecular masses of metabolites were screened out based on known mass shift of 
metabolites such as +16 for hydroxylation. The corresponding EPI (MS/MS) of 
potential metabolites were subsequently compared with that of meisoindigo to 
investigate the fragmentation patterns and obtain information on the metabolite 
structures. Besides, MS/MS/MS of certain product ions gave more evidence about the 
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deduction of fragmentation mechanism. QTOF data also provided the accurate masses 
and potential formulae to further confirm the structures of metabolites. 
2.2.5 Isolation of metabolites by preparative HPLC and MS/MS/MS 
The major metabolites were isolated from a large-scale phenobarbital-induced rat 
liver microsomal inbubation by Agilent 1100 preparative HPLC system (Agilent 
Technologies, Palo Alto, CA, USA) on a Combi-A C18 column (50 × 20 mm, 5 μm) 
(Peeke Scientific, Redwood City, CA, USA) with a guard cartridge at ambient 
temperature. The mobile phase consisted of water (solvent A) and methanol (solvent 
B) and was delivered at a flow rate of 4 mL/min. The linear gradient elution program 
was as follows: 30 % to 100 % B over 20 min, followed by an isocratic hold at 100 % 
B for another 5 min. At 25 min, B was returned to 30 % in 1 min and the column was 
equilibrated for 4 min before the next manual injection. The UV absorbance was 
monitored at 254 nm. All isolated metabolites fractions were lyophilized and 
redissolved in 50 % methanol/water before chiral separation or direct infusion for 
MS/MS/MS analysis. 
2.2.6 Chiral LC-MS/MS analysis 
The rat liver microsomal samples and isolated metabolite fractions were analyzed on a 
Q TRAP™ 3200 LC-MS/MS system from Applied Biosystems / MDS Sciex 
(Concord, Ontario, Canada) coupled to an Agilent 1200 HPLC system (Agilent 
Technologies, Palo Alto, CA, USA). The volume of 20 μl was injected onto a 
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Chiralcel OD-R column (250 × 4.6 mm, 10 μm) (Daicel Chemical Industries, LTD., 
Japan) with a guard cartridge at ambient temperature. The isocratic mobile phase 
consisted of 20 % water (solvent A) and 80 % methanol (solvent B) and was delivered 
at a flow rate of 0.4 mL/min. The total run time was 35 min. The mass spectrometer 
was operated in the positive ion mode with a TurboIonSpray source. The parameter 
conditions were optimized as follows: curtain gas (CUR), 20 (arbitrary units); ion 
source gas 1 (GS1), 30 (arbitrary units); ion source gas 2 (GS2), 40 (arbitrary units); 
source temperature (TEM), 450 ℃; declustering potential (DP), 35 V; collision energy 
(CE), 30 eV; entrance potential (EP), 10 V. Enhanced Q3 Single MS (EMS) was 
utilized to scan the mass range of m/z 50-700. The mass spectrometer and the HPLC 
system were controlled by Analyst 1.4.2 from Applied Biosystems / MDS Sciex. 
2.2.7 Metabolite synthesis and purification 
The starting material meisoindigo (50 mg) was dissolved in methanol (100 mL). After 
adding 10 % palladium on carbon (10 mg), the mixture was placed on the 
hydrogenator apparatus and kept shaking at 40 psi for 2 h at room temperature. 
LC-MS was used to monitor the consumption of starting material. The reaction 
mixture was filtered through filter paper and the filter pad was washed with distilled 
water. The filtrate was evaporated under reduced pressure and the precipitate was 
purified by the same preparative HPLC and column described above. The isocratic 
mobile phase consisted of 50 % water (solvent A) and 50 % methanol (solvent B) and 
was delivered at a flow rate of 4 mL/min within 20 min. The UV absorbance was 
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monitored at 254 nm. All isolated metabolites fractions were evaporated under 
reduced pressure and stored under -20 ℃ before NMR measurement. 
2.2.8 NMR spectroscopy and Synchrotron IR spectroscopy 
Proton NMR spectra of synthesized metabolites were recorded in CDCl3 at room 
temperature on a Bruker DRX 500 MHz NMR spectrometer (Bruker BioSpin GmbH, 
Germany) using tetramethylsilane as an internal standard. 
IR Spectra were recorded through grazing incidence angle in reflection mode on a 
Bruker IFS 66v/S Fourier Transform Infrared spectrometer (FTIR) (Bruker Optics 
GmbH, Germany) with a synchrotron light source. The IR spectral range was from 
approximately 650 cm-1 to 4000 cm-1 with a resolution of 4 cm-1. A KBr beamsplitter 
and mid band MCT infrared detector cooled to 77 K were used. The samples were 
dissolved in acetonitrile and subsequently coated on gold substrate after solvent 
evaporation. Spectra of thin film of samples on gold are directly acquired in the 
vacuum. 
2.2.9 Comparative study on incubations under normoxic and hypoxic conditions 
In normoxic incubation, meisoindigo stock solution in methanol was added to 0.1 M 
Tris buffer (pH 7.4) with rat liver microsomes. The mixture was first shaken for 5 min 
for equilibration in a shaking water bath at 37 ℃. The incubation was then initiated by 
adding β-NADPH solution. The final concentrations of meisoindigo, NADPH and the 
microsomal protein were 10 μM, 1 mM and 1 mg/mL, respectively in a typical 
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incubation mixture (1 mL). The percentage of methanol in the incubation mixture was 
kept less than 1 % (v/v). Aliquots of 100 µL of the incubation mixtures were collected 
at 5, 15, 30 and 60 minutes and the reaction was terminated with the same volume of 
ice-cold acetonitrile to precipitate proteins. Samples were subsequently centrifuged at 
14000 rpm for 15 min. 5 μL of the supernatant was taken and analyzed by LC-MS/MS. 
In hypoxic incubation, meisoindigo and rat liver microsomes were preincubated at 37 
℃ and bubbled with 100 % nitrogen gas (the tip of the nitrogen gas supply was 
submerged approximately 2 mm in the solution) for 5 min. The incubation was then 
initiated by adding β-NADPH solution. The rest of the procedures for sample 
collection and preparation were the same as described above except the continuous 
nitrogen gas supply throughout the study. Negative controls were prepared either by 
substituting microsomal protein previously heated to 70-100 ℃ for 10 min or by 
replacing NAPDH with water under both normoxic and hypoxic conditions. 
The analysis was conducted on a Q TRAP™ 3200 MS/MS system from Applied 
Biosystems / MDS Sciex (Concord, Ontario, Canada) coupled to an Agilent 1200 
HPLC system (Agilent Technologies, Palo Alto, CA, USA). Separations were 
accomplished on a Luna C18 column (150 × 2.0 mm, 5 μm) (Phenomenex, Torrance, 
CA, USA) with a guard cartridge at ambient temperature. The mobile phase consisted 
of 0.1 % formic acid in water (solvent A) and acetonitrile (solvent B) and was 
delivered at a flow rate of 0.2 mL/min. The linear gradient elution program was as 
follows: 30 % to 95 % B over 13 min, followed by an isocratic hold at 95 % B for 
another 7 min. At 20 min, B was returned to 30 % in 1 min and the column was 
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equilibrated for 19 min before the next injection. The total run time for each injection 
was 40 min. The mass spectrometer was operated in the positive ion mode with a 
TurboIonSpray source. Two multiple reaction monitoring (MRM) transitions i.e. 
277.1→234.2 and 279.1→147.1 were used to determine meisoindigo and its 
metabolites at m/z 279, respectively. The declustering potential (DP) and collision 
energy (CE) values were 66 V and 45 eV for meisoindigo, 61 V and 30 eV for the 
metabolites. The other ionization parameters were as follows: curtain gas (CUR), 20 
(arbitrary units); ion source gas 1 (GS1), 40 (arbitrary units); ion source gas 2 (GS2), 
50 (arbitrary units); source temperature (TEM), 650  oC; entrance potential (EP), 10 V. 
The dwell time of each MRM transition was 150 msec. The mass spectrometer and 
the HPLC system were controlled by Analyst 1.4.2 software from Applied 
Biosystems / MDS Sciex. The relative percentages of the components in incubations 
were estimated at different incubation time points based on the integrated peak areas 
of MRM chromatograms. 
2.3 RESULTS 
The proposed fragmentation scheme and product ions of protonated meisoindigo (m/z 
277) are shown in Fig. 2-1. It contains major product ions at m/z 249, 234, 218, 205, 
190, 178, 132 and 104. Loss of CO (28 Da) following gain of one H generated the 
product ion at m/z 249. Loss of CONH (43 Da) following gain of one H generated the 
product ion at m/z 234. Loss of CONCH3 (57 Da) following loss of one H generated 
the product ion at m/z 218. Loss of both CONH and CO generated the product ion at 
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m/z 205. Loss of both CONCH3 and CO following loss of one H generated the 
product ion at m/z 190, which was confirmed by MS/MS/MS. Loss of both CONCH3 
and CONH following gain of two H generated the product ion at m/z 178, which was 
confirmed by MS/MS/MS. Cleavage of the 3,3’ double bond of meisoindigo 
following gain of one H, and subsequent loss of CO at position 2’ following gain of 
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FIG. 2-1. MS/MS spectrum of protonated meisoindigo at m/z 277 and the proposed 
origin of key product ions. 
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The reconstructed extracted ion chromatogram (XIC) from HPLC-QTRAP was shown 
in Fig. 2-2. It was found that the parent drug and its metabolites were detected as their 
protonated molecules. Meisoindigo was eluted at 14.99 min and showed a molecular 
ion (MH+) at m/z 277. Several metabolites were observed and eluted earlier than 
meisoindigo, between 7 and 13 min. Those metabolite peaks formed corresponding to 
masses of m/z 279 (11.19 min, 12.37 min), m/z 265 (9.30 min, 11.87 min), m/z 295 
(7.97 min, 8.86 min, 9.37 min, 10.34 min, 11.59 min) (summarized in Table 2-1). 
From the relative peak areas in Fig. 2-2, meisoindigo remained the largest component, 
while two peaks corresponding to m/z 279 and one peak corresponding to m/z 295 
were regarded as the major metabolites. The chromatographic profiles of meisoindigo 
and its metabolites from UPLC-QTOF showed a significant similarity as that from 
HPLC-QTRAP. Table 2-2 showed the accurate masses and potential molecular 
formulae provided by UPLC-QTOF. 
 





























FIG. 2-2. Reconstructed extract ion chromatogram for meisoindigo and its 
metabolites in rat liver microsomes. 
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TABLE 2-1. HPLC-QTRAP retention times and mass spectra properties for 
meisoindigo and its in vitro metabolites 
 Retention time (min) MH+ m/z of major product ions 







M9,M11,M13,M15 9.37, 10.34 277,267,251,163,134,133 





TABLE 2-2. UPLC-QTOF retention times, potential formula and accurate masses for 






m/z (1+) Del M (Da) 
Measured 
m/z (1+) PPM
Meisoindigo 3.42 C17H13N2O2 277.0977 -0.0001 277.0976 -0.4 
M1+M2 2.07 2.0162 279.1139 1.8 
M3+M4 2.43 
C17H15N2O2 279.1134 2.0153 279.1130 -1.4 
M5+M6 1.65 -12.0005 265.0972 -1.9 
M7(M8) 2.26 
C16H13N2O2 265.0977-11.9996 265.0981 1.5 
1.66 18.0104 295.1081 -0.7 M9,M11,M13,M15 
1.74 18.0111 295.1088 1.7 
1.45 18.0111 295.1088 1.7 
1.56 18.0113 295.1090 2.4 M10,M12,M14,M16 
2.17 
C17H15N2O3 295.1083
18.0101 295.1078 -1.7 
 
2.3.1 Protonated metabolites at m/z 279 
Metabolites at m/z 279 had retention times of 11.19 min and 12.37 min on the HPLC 
system, respectively, and showed 2 Da increase of molecular weight compared with 
parent drug, suggesting they could be direct reduction products or N-demethylation 
followed by mono-oxidation products. The corresponding potential formulae of 
metabolites at m/z 279 based on their accurate masses was C17H15N2O2 (Table 2-2), 
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thus confirming the occurrence of direct reduction. Taking the identical molecular 
formulae with different retention times into account, these two metabolites could be 
isomers. 
Both of the EPI (MS/MS) mass spectra on metabolites at m/z 279 of 11.19 min and 
12.37 min were identical, indicating these two metabolites should be stereoisomers. 
The proposed fragmentation scheme and MS/MS spectrum of protonated metabolites 
at m/z 279 are shown in Fig. 2-3. Loss of H2O (18 Da) generated the product ion at 
m/z 261. Loss of one or two CO generated the product ion at m/z 251 or m/z 223, 
which indicated that reduction had not occurred on either of carbonyl groups. Loss of 
CONH generated the product ion at m/z 234. Cleavage of the 3,3’ bond generated the 
product ions at m/z 147, and m/z 133 which was 1 Da higher than the corresponding 
product ion of meisoindigo at m/z 132, thus indicating the presence of 3,3’ single bond. 
Subsequent loss of CO at position 2 after the cleavage of the 3,3’ bond generated the 
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FIG. 2-3. MS/MS spectrum of protonated M1+M2, M3+M4 at m/z 279 and the 
proposed origin of key product ions. 
 
Since direct double bond reduction caused the generation of two chiral carbon centers 
located in position 3 and 3’, four stereoisomers i.e. M1, M2, M3, M4 at m/z 279 could 
exist with possible absolute configurations of (3-R, 3’-R), (3-S, 3’-S), (3-R, 3’-S), 
(3-S, 3’-R). Among them, M1 and M2, M3 and M4 were assumed as enantiomers of 
each other respectively. In addition, M1 was diastereomer of M3 or M4. M2 was 
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diastereomer of M3 or M4. Considering enantiomers generally show the same 
chromatographic properties with the use of non-chiral column while diastereomers 
seldom do, as well as only two peaks were displayed on the TIC or XIC, the peak 
with retention time of 11.19 min was postulated to be a combination of M1 and M2, 
whereas the other peak with retention time of 12.37 min was postulated to be a 
combination of M3 and M4. 
The chromatographic behaviors of metabolites at m/z 279 on the chiral column further 
confirmed this postulation. The two peaks with retention time of 11.19 min and 12.37 
min on non-chiral column (Fig. 2-2) were split into four peaks on chiral column, with 
retention times of 18.61 min, 21.44 min, 25.24 min and 27.69 min, respectively (Fig. 
2-4 A). Interestingly, after separation of the two pairs of enantiomers through 
preparative HPLC, one pair of enantiomer (M1+M2) corresponded the leftmost and 
rightmost peaks with the retention times of 18.70 min and 27.68 min (Fig. 2-4 B), 
whereas the other pair (M3+M4) corresponded the two peaks in the middle with the 
retention times of 21.33 min and 24.96 min (Fig. 2-4 C), which suggesting the chiral 
structure difference between M1 and M2 was larger than that between M3 and M4. 
Furthermore, the isolated pair of enantiomer (M1+M2) showed two additional small 
peaks happening to correspond to the other pair (M3+M4) (Fig. 2-4 B), while the 
isolated (M3+M4) only showed two peaks (Fig. 2-4 C), which strongly indicated that 
(M1+M2) was unstable, automatically converting to (M3+M4). Hence the absolute 
configurations of (M1+M2) could be (3-R, 3’-R) and (3-S, 3’-S). Based on each 
stereoisomer’s chromatographic peak areas shown in Fig. 2-4 A, the reduction 
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metabolism of meisoindigo was found to be stereoselective. One pair of enantiomer 
(M3+M4) showed a higher abundance than the other pair (M1+M2). Within both of 
these two pairs of enantiomers, the more polar stereoisomer eluted first was always of 
higher abundance than the less polar one (18.70 min versus 27.68 min, 21.33 min 
versus 24.96 min). 
The hydrogenation of red meisoindigo generated colorless products in methanol 
solution. Diluted products showed the same retention times and fragmentation 
patterns on LC-MS/MS as the two metabolites at m/z 279 from microsomal sample. 
After isolation by preparative HPLC and solvent evaporation, two white solids of 
metabolites were obtained. The proton NMR signals of meisoindigo, M1+M2, and 
M3+M4 were assigned in Table 2-3, respectively. The significant similarity in proton 
NMR signals of M1+M2 and M3+M4 further confirmed the diastereomer relationship 
between them. Compared with the chemical shift values of meisoindigo, the chemical 
shift values of both M1+M2 and M3+M4 more or less shifted to relatively high field 
region, due to the breakdown of long conjugation within the whole molecule caused 
by the forming of 3,3’ single bond. 
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FIG. 2-4. Extracted ion chromatograms on the chiral column corresponding to 
M1+M2+M3+M4 (A), M1+M2 (B) and M3+M4 (C) at m/z 279. 
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The synchrotron infrared absorption spectra of two isolated metabolites at m/z 279 
were very similar and shown in Fig. 2-8 (A). The broad band around 3200-3400 cm-1 
was assigned to be NH stretching vibration. The band around 2800-2900 cm-1 was 
assigned to be CH3 stretching vibration. The band around 1600 cm-1 was assigned to 
be C=O stretching vibration. These characteristic absorption bands further confirmed 
the presence of NH, CH3 and C=O. 
 
TABLE 2-3. 1H-NMR data for meisoindigo, M1+M2, and M3+M4 
Position Meisoindigo M1+M2 M3+M4 
4 9.13 (1H, d, 8.0Hz) 7.26 (1H, t, 8.0Hz) 7.23 (1H, t, 8.0Hz) 
5 7.08 (1H, m) 6.98 (1H, m) 6.95 (1H, m) 
6 7.38 (1H, t, 7.5Hz) 7.15 (1H, m) 7.12 (1H, m) 
7 6.79 (1H, m) 6.74 (1H, m) 6.72 (1H, m) 
4’ 9.20 (1H, d, 8.0Hz) 7.33 (1H, t, 8.0Hz) 7.30 (1H, t, 8.0Hz) 
5’ 7.05 (1H, m) 6.95 (1H, m) 6.92 (1H, m) 
6’ 7.32 (1H, t, 7.5Hz) 7.08 (1H, t, 8.0Hz) 7.05 (1H, t, 8.0Hz) 
7’ 6.81 (1H, m) 6.81 (1H, t, 8.5Hz) 6.78 (1H, m) 
NCH3 3.30 (3H, s) 3.17 (3H, s) 3.14 (3H, s) 
NH 7.81 (1H, br.s) 7.58 (1H, br.s) 7.48 (1H, br.s) 
3 ⎯ 4.23 (1H, dd, 3.5Hz, 24.0Hz) 
4.20 (1H, dd, 3.5Hz, 
24.0Hz) 
3’ ⎯ 4.32 (1H, dd, 3.5Hz, 26.0Hz) 
4.30 (1H, dd, 3.5Hz, 
27.0Hz) 
 
Therefore, M1+M2 was tentatively identified as a pair of (3-R, 3’-R) and (3-S, 3’-S) 
reduced-meisoindigo enantiomers with two hydrogens located at the same side of 
3,3’-single bond, whereas M3+M4 as another pair of (3-R, 3’-S) and (3-S, 3’-R) 
enantiomers with two hydrogens located at the opposite sides. 
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2.3.2 Protonated metabolites at m/z 265.  
Metabolites at m/z 265 had retention times of 9.30 min and 11.87 min on the HPLC 
system, respectively, and showed 12 Da decrease of molecular weight compared with 
parent drug, suggesting they could be direct reduction followed by N-demethylation 
products. The corresponding potential formulae of metabolites at m/z 265 based on 
their accurate masses was C16H13N2O2 (Table 2-2), thus confirming this postulation. 
Taking the identical molecular formulae with different retention times into account, 
these two metabolites could be isomers. 
Both of the EPI (MS/MS) mass spectra on metabolites at m/z 265 of 9.30 min and 
11.87 min were identical, indicating these two metabolites should be stereoisomers. 
The proposed fragmentation scheme and MS/MS spectrum of protonated metabolites 
at m/z 265 are shown in Fig. 2-5. Loss of H2O generated the product ion at m/z 247, 
and subsequent loss of CO generated m/z 219. Loss of one or two CO generated the 
product ion at m/z 237 or m/z 209, which indicated that reduction had not occurred on 
either of carbonyl groups. Cleavage of the 3,3’ bond generated the product ion at m/z 
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FIG. 2-5. MS/MS spectrum of protonated M5+M6, M7(M8) at m/z 265 and the 
proposed origin of key product ions. 
 
Due to the generation of two chiral carbon centers located in position 3 and 3’, four 
stereoisomers i.e. M5, M6, M7, M8 at m/z 265 could exist with possible absolute 
configuration of (3-R, 3’-R), (3-S, 3’-S), (3-R, 3’-S), (3-S, 3’-R). Interestingly, 
reduction followed by N-demethylation led to the generation of the same segments on 
the both sides of 3-3’ single bond. M5 (3-R, 3’-R), M6 (3-S, 3’-S) were enantiomers 
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of each other so that they were combined into one peak on the TIC or XIC with 
retention times of 9.30 min. However, M7 (3-R, 3’-S), M8 (3-S, 3’-R) were actually 
the identical compound, due to the presence of an internal symmetrical center at the 
midpoint of 3-3’ single bond. M7 (namely M8) was a meso compound with retention 
times of 11.87 min. Furthermore, M7 (M8) exhibited a higher abundance than the pair 
of enantiomer (M5+M6) (Fig. 2-2), suggesting metabolites of m/z 265 also showed 
stereoselective metabolism in this case.  
Therefore, M5+M6 was tentatively identified as a pair of (3-R, 3’-R) and (3-S, 3’-S) 
N-demethyl-reduced-meisoindigo enantiomers with two hydrogens located at the 
same side of 3,3’-single bond, whereas M7 (M8) as one meso compound with two 
hydrogens located at the opposite sides. 
2.3.3 Protonated metabolites at m/z 295.  
Metabolites at m/z 295 had retention times of 7.97 min, 8.86 min, 9.37 min, 10.34 min 
and 11.59 min on the HPLC system, respectively, and showed 18 Da increase of 
molecular weight compared with parent drug, suggesting they could be direct 
reduction followed by mono-oxidation products. The corresponding potential 
formulae of metabolites at m/z 295 based on their accurate masses was C17H15N2O3 
(Table 2-2), thus confirming this postulation. Taking the identical molecular formulae 
with different retention times into account, these five metabolites could be isomers. 
There were two types of EPI (MS/MS) mass spectra on metabolites at m/z 295. One 
type was the identical EPI of metabolites with retention times of 9.37 min and 10.34 
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min, indicating these two metabolites should be stereoisomers. The proposed 
fragmentation scheme and MS/MS spectrum of this type are shown in Fig. 2-6. Loss 
of H2O generated the product ion at m/z 277. Loss of CO generated the product ion at 
m/z 267. Loss of CONH generated the product ion at m/z 251. Cleavage of the 3,3’ 
bond generated the product ions at m/z 163 and m/z 133, of which only m/z 163 was 
16 Da higher than the corresponding product ion of reduced-meisoindigo at m/z 147, 
thus indicating hydroxylation had occurred at one of the positions 4, 5, 6 and 7. 
Subsequent loss of CO at position 2 after the cleavage of the 3,3’ bond generated the 
product ions at m/z 134. The other type was the identical EPI of metabolites with 
retention times of 7.97 min, 8.86 min and 11.59 min, indicating these three 
metabolites should be stereoisomers. The proposed fragmentation scheme and 
MS/MS spectrum of this type are shown in Fig. 2-7. Loss of both H2O and CO 
generated the product ion at m/z 249. Cleavage of the 3,3’ bond generated the product 
ions at m/z 147 and m/z 149, of which only m/z 149 was 16 Da higher than the 
corresponding product ion of reduced-meisoindigo at m/z 133, thus indicating 
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FIG. 2-6. MS/MS spectrum of protonated M9, M11, M13, M15 at m/z 295 and the 











































FIG. 2-7. MS/MS spectrum of protonated M10, M12, M14, M16 at m/z 295 and the 
proposed origin of key product ions. 
 
Reduction followed by phenyl single oxidation led to two different types of position 
isomers. Considering the generation of two chiral carbon centers located in position 3 
and 3’, the first type could involve M9 (3-R, 3’-R), M11 (3-S, 3’-S), M13 (3-R, 3’-S), 
M15 (3-S, 3’-R), with single hydroxyl group at position 4, 5, 6 or 7. The second type 
could involve M10 (3-R, 3’-R), M12 (3-S, 3’-S), M14 (3-R, 3’-S), M16 (3-S, 3’-R), 
with single hydroxyl group at position 4’, 5’, 6’ or 7’. For each stereoisomer, there 
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were four maximal possibilities regarding the specific positions of hydroxyl group on 
the phenyl ring. In addition, based on chromatographic peak areas shown in Fig. 2-2, 
the first type i.e. M9, M11, M13, M15 showed a higher abundance than the second 
type i.e. M10, M12, M14, M16, which suggested that the reduction followed by 
mono-oxidation metabolism of meisoindigo was regioselective. 
The synchrotron IR absorption spectra of metabolites at m/z 295 isolated by analytical 
HPLC were very similar. The IR spectrum of the most concentrated one was shown in 
Fig. 2-8 (B). The intensity of broad band around 3000-3500 cm-1 relative to the band 
around 2800-2900 cm-1 was higher compared with Fig. 2-8 (A), indicating the 
presence of both OH and NH. The OH stretching vibration band was also found to be 
broad and slightly lower than NH stretching band. The band around 2800-2900 cm-1 
was assigned to be CH3 stretching vibration. The band around 1600 cm-1 was assigned 
to be C=O stretching vibration. These characteristic absorption bands further 
confirmed the presence of NH, OH, CH3 and C=O. 
Therefore, M9, M11, M13, M15 were within the bounds of (3-R, 3’-R), (3-S, 3’-S), 
(3-R, 3’-S), (3-S, 3’-R) monohydroxyl-reduced-meisoindigo isomers with single 
hydroxyl group located at position 4, 5, 6 or 7, whereas M10, M12, M14, M16 falling 
within another type of isomers with single hydroxyl group located at position 4’, 5’, 6’ 
or 7’. 
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FIG. 2-8. Infrared absorption spectra of mesoindigo metabolites at m/z 279 (A) and 




2.3.4 Incubations under normoxic and hypoxic conditions. 
The relative percentages of meisoindigo and its metabolites at m/z 279 in incubations 
with rat liver microsomes at various incubation time points are given in Table 2-4. 
The results showed that the difference of relative percentages between normoxic and 
hypoxic incubations was the most significant at 5 min. Approximately 95.81 % of 
meisoindigo, 1.92 % of M1+M2, and 2.27 % of M3+M4 were found in the 5-min 
incubation of meisoindigo under normoxic conditions, whereas 66.80 % of 
meisoindigo, 13.12 % of M1+M2, and 20.08 % of M3+M4 were observed in the 
5-min incubation of meisoindigo under hypoxic conditions, thus indicating the 
occurrence of rapid reductive metabolism of meisoindigo (Table 2-4). The difference 
of relative percentages between normoxic and hypoxic incubations attenuated with 
time, until similar relative percentages were found in the both normoxic and hypoxic 
incubations at 60 min. As a whole, a quicker onset of the metabolism under hypoxic 
conditions was obtained as compared to that under normoxic conditions, suggesting 
oxygen exposure strongly inhibits the in vitro reductive metabolism of meisoindigo in 
rat liver microsomes. 
 
TABLE 2-4. Relative percentages of identified components in incubations of 
meisoindigo with rat liver microsomes under normoxic and hypoxic conditions 
Normoxic (%) Hypoxic (%) Time 
(min) Meisoindigo M1+M2 M3+M4 Meisoindigo M1+M2 M3+M4 
5 95.81 1.92 2.27 66.80 13.12 20.08 
15 60.24 15.54 24.23 42.18 21.99 35.83 




This is the first investigation of the in vitro stereoisomeric metabolites of meisoindigo 
in rat liver microsomes, by achiral and chiral LC-MS/MS, as well as other relevant 
techniques. In the present study, rat liver microsomes were chosen because rats 
express two major cytochrome P450 isoforms that are oligomerically related to 
human CYP3A4, CYP3A1 and CYP3A2 (Nelson et al., 1996). Besides, rat liver 
microsomes are readily available though simple preparation. Although the metabolism 
study in human liver microsomes is not involved yet in this study, the relevant results 
obtained showed a qualitative similarity in metabolite profiles of meisoindigo 
between rat liver microsomes and human liver microsomes. In addition, the 
metabolite profile of meisoindigo in rat liver microsomes is more comprehensive than 
that in human liver microsomes. Thus the findings regarding metabolite profile in rat 
liver microsomes are of considerable importance. 
The abundance of the minor metabolites is generally very low, especially in 
incubation with low substrate concentration, but is increased relative to other 
metabolites at higher substrate concentrations. Considering the typical concentration 
range (10-50 μM) in metabolite identification experiments (Chen et al., 2007), the 
upper limit concentration, i.e. 50 μM, was adopted. Furthermore, minimal sample 
cleanup was performed, because the nature, number, and concentrations of 
metabolites present were unknown, and it was therefore impossible to determine if 
any would be lost during sample preparation (Clarke et al. 2001). 
On the basis of molecular masses, fragmentation patterns, as well as potential 
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formulae of the metabolites and meisoindigo, three metabolic pathways of 
meisoindigo in male rat liver microsomes were proposed as direct 3,3’ double bond 
reduction, reduction followed by N-demethylation, as well as reduction followed by 
phenyl mono-oxidation (Fig. 2-9). Among them, direct 3,3’ double bond reduction 
was one-step reaction and thus the predominant pathway. The other two parallel 
metabolic pathways were two-step reactions and thus secondary pathways. 
Interestingly, the first two metabolic pathways of meisoindigo were found to be 
stereoselective, while the third one was both stereoselective and regioselective. In the 
cases of either M3+M4 versus M1+M2 or M7(M8) versus M5+M6, the pair of (3-R, 
3’-S) and (3-S, 3’-R) enantiomer with two hydrogens located at the opposite sides 
showed a much higher abundance than the other pair of (3-R, 3’-R) and (3-S, 3’-S) 
enantiomer with two hydrogens located at the same sides.  
Proton NMR spectroscopy nuclear Overhauser effect (NOE) experiments were 
conducted to explore the NOE signal difference caused by distinct spatial distance 
between 3H and 3’H within the two pairs of synthetic enantiomers, namely M1+M2 
and M3+M4. However, the results showed that there was no significant difference in 
the NOE spectra between synthetic M1+M2 and M3+M4, when 3H and 3’H were 
irradiated, respectively. Other methods such as optical rotary dispersion (ORD), 
circular dichroism (CD) or X-ray crystallography could be conducted to confirm the 
assignment of the absolute configurations of M1+M2 and M3+M4. However, further 
investigation on the specific absolute configurations of four stereoisomers i.e. M1, M2, 
M3, M4 could be very challenging due to the rapid enantiomer interconversion 
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FIG. 2-9. Proposed metabolic pathway of meisoindigo in rat liver microsomes. 
 
In terms of chiral chromatography analysis, a good separation of metabolite 
stereoisomers could not be achieved through gradient elution mobile phase, which is 
typically used for achiral chromatography analysis. Isocratic mobile phase was finally 
adopted to successfully separate the two pairs of enantiomers at m/z 279 
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simultaneously on a Daicel Chiralcel OD-R column. But this chiral column didn’t 
work well on the separation of stereoisomeric metabolites at m/z 265 and m/z 295, 
probably owing to their relatively low quantity. Another possible reason might be the 
specific packing material of Chiralcel OD-R column was only suitable for the chiral 
separation of stereoisomeric metabolites at m/z 279 rather than the other two. In this 
case, other different types of chiral columns could be considered. 
Although the chromatographic peak at m/z 295 with retention time of 9.37 min was 
regarded as the major metabolite, another peak of the pair of enantiomers (M5+M6) 
with retention time of 9.30 min was almost co-eluted with it (Fig. 2-2). More sensitive 
scan type multiple reactions monitoring (MRM) couple with UPLC showed that this 
peak at 9.37 min in Fig. 2-2 was actually more than one component and combined 
with three individual peaks showing m/z 295. Due to the chromatographic complexity 
and trace amount of these minor metabolites, microsomal incubation samples had 
been directly tried on the online LC-NMR 600 MHz equipped with a cryoprobe from 
Bruker BioSpin. Unfortunately, injection volume was limited by the bulk 
concentration of microsomal matrix contaminants in the first 5 minutes, which thus 
diluted the eluted components entering into the NMR detection region. Analytical 
HPLC was subsequently tried to isolate and accumulate the minor metabolites at m/z 
295 and m/z 265 for further characterization by 1.7 mm Micro-CryoProbe NMR 600 
MHz from Bruker BioSpin. However, the accumulated quantity was still unable to 
meet the minimal requirement of this special NMR measurement with the lowest 
detection of limit at present. Therefore, chemical synthesis has to be the last resort. 
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Further work would be needed to synthesize the possible minor metabolites and 
isolate the stereoisomers by chiral chromatography followed by NMR structural 
characterization. In particular, the specific position of OH group in stereoisomeric 
monohydroxyl-reduced-meisoindigo is a vital aspect to be investigated. Since both 
NCH3 at position 8 and NH at position 8’ donate electrons into the two phenyl ring 
systems, the highest electron density should be located at ortho positions (i.e. 7 or 7’) 
and para positions (i.e. 5 or 5’). In view of the offset by steric hindrance of OH group 
at ortho positions, it could be predicted that para positions (i.e. 5 or 5’) would be thus 
the most reactive towards perferryl oxygen complex [FeO]3+ from the perspective of 
CYP450 oxidation mechanism. 
Considering synchrotron IR spectroscopy provided a much greater detection of limit 
than conventional IR technique due to the high brightness of synchrotron IR source, it 
was employed for the first time to further confirm the structures of metabolite within 
mg level after isolation and accumulation by analytical HPLC. The IR measurement 
was performed in the vacuum to remove the signals caused by H2O and CO2 from the 
air as much as possible, thus achieving a satisfactory signal to noise ratio. It should be 
noted that synchrotron IR is only applicable for those limited instances, in which the 
structural difference between metabolite and parent drug is due to characteristic IR 
functional groups, such as hydroxyl group, carbonyl group, amino group etc. Hence, 
synchrotron IR can only be a supplementary tool to conventional structural 
identification approaches, i.e., MS and NMR. 
The comparative metabolite profiling using rat liver microsomes in the normoxic and 
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hypoxic incubations further confirmed the occurrence of reductive metabolism of 
meisoindigo. Based on a report on the reductive metabolism of meisoindigo analogues 
(Kohno et al., 2005), it is possible to speculate that NADPH-cytochrome P450 
reductase (P450R) in rat liver microsomes could be the enzyme responsible for the 
initiation of reductive activation of meisoindigo through the formation of a superoxide 
radical by transferring one electron from the electron donor i.e. NADPH. This 
proposed mechanism can be confirmed by investigating the metabolism of 







                                                                      
CHAPTER 3 
Metabolism of meisoindigo in rat, pig and human liver 
microsomes by UFLC-MS/MS 
                                                                      
3.1 INTRODUCTION 
In our previous study in Chapter 2, in vitro stereoisomeric metabolites of meisoindigo 
with the substrate concentration of 50 μM in male rat liver microsomes were 
identified by achiral and chiral liquid chromatography / tandem mass spectrometry 
(LC-MS/MS), together with proton NMR spectroscopy and synchrotron infrared 
spectroscopy. Three parallel metabolic pathways of meisoindigo in male rat liver 
microsomes were thereby proposed in Chapter 2 as direct 3,3’ double bond reduction, 
reduction followed by N-demethylation, as well as reduction followed by phenyl 
mono-oxidation. 
Although the use of Enhanced Q3 Single MS (EMS) in combination with Enhanced 
Product Ion (EPI) led to considerably successful metabolite detection and structural 
elucidation in our previous study, the approach is disadvantaged by the limited 
detection sensitivity of the full scan mode due to the high background signal from the 
microsomal matrices. The search for metabolites using precursor ion scan (PI) and 
neutral loss scan (NL) shows a relatively high sensitivity but assumes that the 
metabolites have a common fragment with the parent drug. Unfortunately, based on 
 58
our previous results, the metabolites of meisoindigo at m/z 279, 265, 295 all 
underwent 3,3’ double bond reduction of the parent drug, thus resulting in distinct 
fragmentation mechanisms from that of the parent drug. Hence, characteristic 
fragment ions could not be identified for the PI or NL scan. Considering a hybrid 
triple quadrupole linear ion trap (QTRAP) set to perform multiple reaction monitoring 
(MRM) offers high sensitivity, selectivity, and a good dynamic range, MRM 
screening could be an alternative approach for metabolite detection, especially for the 
minor metabolites with trace amounts. Besides, MRM could be used to carry out 
simultaneous quantitative analysis of the parent drug disappearance and metabolite 
appearance in liver microsomes across multiple species. With appropriate dwell time 
and fixed number of MRM transitions, relative quantification could be achieved 
attributed to the fast scanning capability of the hybrid triple quadrupole linear ion trap 
under the linear ion trap mode that enabled enough data points to be collected across 
the chromatographic peaks for quantification. A higher number of data points for a 
chromatographic peak also provided reproducible peak areas for quantification 
purposes. (Shou et al., 2005) 
On the other hand, stereoisomeric reductive plus phenyl mono-oxidative metabolites 
at m/z 295 were speculated to be very close chromatographic peaks due to tiny 
chromatographic profile differences, caused by different specific positions of OH 
group on the two phenyl rings, as well as the different absolute configurations at 
positions 3 and 3’ discussed in Chapter 2. Considering ultra fast liquid 
chromatography (UFLC) has the capability in higher chromatographic resolution 
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through smaller particle packing column material (2.2 μm) and higher pressure pumps 
as compared to conventional HPLC, UFLC could be utilized to screen out more 
stereoisomeric reductive plus phenyl mono-oxidative metabolites at m/z 295, or even 
other types of minor metabolites of meisoindigo. 
Herein, considering interspecies variability as an important internal factor affecting 
drug metabolism, the purpose of the present study in Chapter 3 was to qualitatively 
and quantitatively investigate the in vitro metabolism of meisoindigo in liver 
microsomes from three species rat, pig and human with different genders utilizing 
UFLC coupled with QTRAP, and establish the metabolic profiles in terms of 
metabolite identification, metabolic stability, metabolite formation and gender effect. 
Identification of the phase I metabolites and the semi-quantitative analysis of the 
parent disappearance as well as the corresponding metabolite formation along the 
incubation time in liver microsomes across male and female rats, pigs, and humans, 
were conducted by monitoring MRM transitions at the relevant therapeutic 
concentration levels of 50 μM and 1 μM, respectively (Chen et al., 2007). Responses 
of the parent and the metabolites were plotted along the incubation time for the three 
species, and the differences among species are subsequently identified. 
3.2 MATERIALS AND METHODS 
3.2.1 Chemicals 
All chemicals were of analytical grade and used without further purification. 
Meisoindigo was provided by Institute of Materia Medica, Chinese Academy of 
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Medical Sciences and Peking Union Medical College, Beijing, China. Bradford 
reagent, bovine serum albumin (BSA), formic acid and β-NADPH were purchased 
from Sigma Chemical Co. (St. Louis, Mo, USA). HPLC grade methanol and 
acetonitrile were purchased from Fisher Scientific Co. (Fair Lawn, NY, USA). 
Milli-Q water was obtained from a Millipore water purification system (Billerica, MA, 
USA) and used to prepare buffer solutions and other aqueous solutions.  
3.2.2 Liver microsomal preparation and origin 
Pooled different gender rat and pig liver microsomes were prepared according to the 
method reported previously (Gibson and Skett, 1994). Three male and three female 
Sprague-Dawley (SD) rats were obtained from Animal Holding Unit, National 
University of Singapore. Three male and three female Large White-Landrace-Duroc 
pigs were obtained from Buroh Lane Abattoir, Primary Industries Pte Ltd, Singapore. 
Rats were euthanized with CO2 after a 24-h fasting period. Pigs were slaughtered by 
electric shot at the abattoir. The pooled extracted liver microsomes were suspended in 
0.1 M Tris buffer (PH 7.4) and stored at -80 ℃ before use. The rat and pig 
microsomal protein contents were determined by Bradford assay method, using BSA 
as the standard protein (Bradford, 1976). Pooled male human liver microsomes from 
10 individuals and pooled female human liver microsomes from 10 individuals were 
both purchased from BD GentestTM (Woburn, MA, USA). The human microsomal 
protein contents were 20 mg/ml. 
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3.2.3 Liver microsomal incubations 
Meisoindigo stock solution in methanol was added to 0.1 M Tris buffer (pH 7.4) with 
rat, pig or human liver microsomes respectively. The mixture was first shaken for 5 
min for equilibration in a shaking water bath at 37 ℃. The incubation was then 
initiated by adding β-NADPH solution. The final concentrations of meisoindigo, 
NADPH and the microsomal protein were 50 μM, 1 mM and 1 mg/mL, respectively 
in a typical incubation mixture (1 mL) for metabolite identification study. The final 
concentrations of meisoindigo, NADPH and the microsomal protein were 1 μM, 1 
mM and 0.5 mg/mL, respectively in a typical incubation mixture (1 mL) for metabolic 
stability and metabolite formation studies. The percentage of methanol in the 
incubation mixture was kept less than 1 % (v/v). For metabolite identification study, 
samples were incubated for 60 min. For metabolic stability and metabolite formation 
studies, aliquots of 100 µL of the incubation sample mixtures were collected at 5, 10, 
20, 30, 40, 50, 60 and 90 minutes. The reaction was terminated with the same volume 
of ice-cold acetonitrile to precipitate proteins and the samples were subsequently 
centrifuged at 14000 rpm for 15 min. Negative controls were prepared with NADPH 
added followed by immediate termination using ice-cold acetonitrile and set as the 0 
minute aliquots. All experiments were carried out in triplicate. A 5 μL supernatant 
was taken and analyzed by UFLC-MS/MS. 
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3.2.4 UFLC-MS/MS analysis 
The negative controls and samples were analyzed on a Q TRAP™ 3200 MS/MS 
system from Applied Biosystems / MDS Sciex (Concord, Ontario, Canada) coupled to 
a ProminenceTM UFLC system (Shimadzu, Japan). Separations were accomplished on 
a Shim-pack XR-ODS column (50 × 3.0 mm, 2.2 μm) (Shimadzu, Japan) with a guard 
cartridge at temperature of 80 ℃. The mobile phase consisted of 0.1 % formic acid in 
water (solvent A) and acetonitrile (solvent B) and was delivered at a flow rate of 0.8 
mL/min. The linear gradient elution program was as follows: 5 % to 95 % B over 14 
min, followed by an isocratic hold at 95 % B for another 1 min. At 15 min, B was 
returned to 5 % in 0.1 min and the column was equilibrated for 4.9 min before the 
next injection. The total run time for each injection was 20 min. The mass 
spectrometer was operated in the positive ion mode with a TurboIonSpray source. A 
list of 9 MRM transitions with the addition of parent drug in Table 3-1 was used to 
cover the most common phase I biotransformation reactions of meisoindigo. The Q1, 
Q3, declustering potential (DP), and collision energy (CE) values were based on the 
phase I biotransformation prediction of meisoindigo by MetaboliteID 1.4 software 
from Applied Biosystems / MDS Sciex as well as the previous EMS and EPI results 
of meisoindigo and its phase I metabolites. The other ionization parameters were as 
follows: curtain gas (CUR), 30 (arbitrary units); ion source gas 1 (GS1), 40 (arbitrary 
units); ion source gas 2 (GS2), 50 (arbitrary units); source temperature (TEM), 650 ℃; 
entrance potential (EP), 10 V. The dwell time of each MRM transition was 150 msec. 
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The mass spectrometer and the UFLC system were controlled by Analyst 1.4.2 
software from Applied Biosystems / MDS Sciex.  
 













Parent 0 277.1 234.2 66 45 
Hydrogenation 2 279.1 147.1 60 30 
Hydrogenation+ demethylation -12 265.1 133.1 60 30 
Hydrogenation+oxidation 18 295.1 163.1 60 30 
Hydrogenation+oxidation 18 295.1 147.1 60 30 
Oxidation 16 293.1 249.1 60 40 
Dioxidation 32 309.1 265.1 60 40 
Demethylation -14 263.1 235.1 60 40 
Hydrogenation+dioxidation 34 311.1 178.1 60 30 
 
3.2.5 Metabolite identification 
The strongest MRM signals with ion counts higher than 300 were selected. The 
associated EPI scans were subsequently triggered, ranging from m/z 50 to 300 at a 
scan rate of 4000 amu/s with dynamic fill in the linear ion trap. The CE value was set 
at 40 eV with a spread of 5 eV. The search for meisoindigo metabolites was performed 
manually by interpretation of MRM chromatograms and EPI spectra. The 
corresponding EPI of potential metabolites were compared with that of meisoindigo 
to investigate the fragmentation patterns and obtain information on the metabolite 
structures. The phase I biotransformations predicted by MetaboliteID 1.4 software 
were also confirmed by the EPI spectra. 
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3.2.6 Metabolic stability calculations and statistical analysis 
The corresponding MRM transition of meisoindigo was selected and used for peak 
configuration in Analyst 1.4.2 for semi-quantitation. In the determination of the in 
vitro half-life (t1/2), the peak areas of meisoindigo were converted to parent remaining 
percentages, using the t=0 peak area values as 100%. The parent remaining 
percentages of meisoindigo were plotted against the microsomal incubation time 
using Microsoft Excel. Data points were the average of three measurements with 
standard deviations as the error bars. The in vitro t1/2 (in units of min) was calculated 
from the slope of the linear regression of the natural logarithm of the parent remaining 
percentage versus incubation time according to the following formula (Obach et al., 
1997; Obach, 1999).  
t1/2 = slope
ln2  
In vitro intrinsic clearance (CLint) (in units of ml/min/kg) was calculated from the t1/2 











It was assumed that rats and humans have 40 and 25.7 g of liver per kg body weight, 
respectively (Davies and Morris, 1993). Microsomal protein content of the livers was 
assumed to be 45 and 52.5 mg of microsomal protein per g of liver for rats (Houston, 
1994) and humans (Iwatsubo et al., 1997), respectively. Microsomal protein content 
of the incubation was set as 0.5 mg of microsomal protein per mL of inbubation for 
both rats and humans as described above. 
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Statistical comparisons in the rates of meisoindigo metabolism among three species 
were made using one way analysis of variance (ANOVA) by GraphPad Prism 4 
software. Independent two sample t-tests were performed to evaluate the metabolism 
differences caused by genders. Differences were considered as statistically significant 
when p value was less than 0.05. 
3.2.7 Metabolite formation 
The corresponding MRM transitions of meisoindigo metabolites were selected and 
used for peak configuration in Analyst 1.4.2 for semi-quantitation. Peak areas of 
metabolites were calculated and plotted against the microsomal incubation time using 
Microsoft Excel. Data points were the average of three measurements with standard 
deviations as the error bars. 
3.3 RESULTS 
3.3.1 Metabolite identification 
Table 3-2 outlines the metabolites of meisoindigo generated in male rat, pig and 
human microsomes after incubation for 60 min with substrate concentration of 50 uM. 
Significant metabolites were searched out with the following six MRM transitions 
except 309.1→265.1 and 311.1→178.1. Female metabolite profiles were found to be 
similar as their corresponding male ones for the same species, while showed lower 




TABLE 3-2. Meisoindigo metabolites found in liver microsomes from the three male 
species after incubation with substrate concentration of 50 uM for 60 min 
Metabolite MRM transition Retention time (min) Rat Pig Human 
M279-1 4.34 √ √ √ 
M279-2 
279.1→147.1 
4.92 √ √ √ 
M265-1 3.25 √ √ √ 
M265-2 265.1→133.1 4.27 √ √ √ 
M295-1 3.08 √ ⎯ ⎯ 
M295-2 3.16 √ ⎯ ⎯ 
M295-3 3.24 √ √ √ 
M295-4 3.34 √ ⎯ ⎯ 
M295-5 3.89 √ √ √ 
M295-6 4.87 ⎯ ⎯ √ 
M295-7 5.05 ⎯ ⎯ √ 
M295-8 
295.1→163.1 
6.15 √ ⎯ √ 
M295-9 2.50 √ ⎯ √ 
M295-10 2.93 √ √ √ 
M295-11 3.04 √ √ √ 
M295-12 3.56 √ √ √ 
M295-13 4.21 √ √ √ 
M295-14 4.86 √ √ √ 
M295-15 5.06 √ √ √ 
M295-16 
295.1→147.1 
5.28 √ ⎯ √ 
M293-1 4.87 √ √ √ 
M293-2 5.08 ⎯ ⎯ √ 
M293-3 5.28 √ √ ⎯ 
M293-4 5.44 ⎯ √ √ 
M293-5 
293.1→249.1 
5.71 √ √ √ 
M263 263.1→235.1 4.79 ⎯ √ √ 
√, metabolite detected; ⎯, metabolite not detected. 
 
3.3.1.1 MRM transition 279.1→147.1 and 265.1→133.1 
All of the three species gave rise to two reductive metabolite isomers i.e. M279-1 and 
M279-2 with retention times of 4.34 min and 4.92 min, as well as reductive plus 
N-demethyl metabolite isomers i.e. M265-1 and M265-2 with retention times of 3.25 
min and 4.27 min (Table 3-2). The abundances of these two types of metabolites in rat 
liver microsomes were much higher than those in the other two liver microsomes, 
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whereas the abundances of these metabolites in pig and human liver microsomes were 
comparable. The proposed fragmentation scheme and MS/MS spectrum of these two 
types of metabolites were reported in Chapter 2. 
3.3.1.2 MRM transition 295.1→163.1 
Six, two and five reductive plus phenyl mono-oxidative (at positions 4, 5, 6 or 7) 
metabolite isomers were generated in rat, pig and human liver microsomes, 
respectively (Table 3-2). Among them, M295-3 (3.24 min) and M295-5 (3.89 min) 
were observed in all of the three species. M295-1 (3.08 min), M295-2 (3.16 min) and 
M295-4 (3.34 min) were only observed in rat liver microsomes, whereas M295-6 
(4.87 min) and M295-7 (5.05 min) were only observed in human liver microsomes, 
and not in the other two animal microsomes. The abundances of the common 
metabolites in all three species were comparable, whereas the two human unique 
metabolites showed relative low abundances (Fig. 3-1). The proposed fragmentation 






















































































FIG. 3-1. Extracted ion chromatograms of MRM transition (295.1→163.1) for 




3.3.1.3 MRM transition 295.1→147.1 
Eight, six and eight reductive plus phenyl mono-oxidative (at positions 4’, 5’, 6’ or 7’) 
metabolite isomers were generated in rat, pig and human liver microsomes, 
respectively (Table 3-2). Among them, six common metabolites were observed in all 
of the three species, whereas M295-9 (2.50 min) and M295-16 (5.28 min) were only 
observed in rat and human liver microsomes rather than pig liver microsomes. The 
abundances of the common metabolites in all of the three species were distinct, 
especially the two major metabolites in human liver microsomes i.e. M295-14 (4.86 
min) and M295-15 (5.06 min) showed relative high abundances as compared to the 
other two animal species (Fig. 3-2). The proposed fragmentation scheme and MS/MS 








































































































FIG. 3-2. Extracted ion chromatograms of MRM transition (295.1→147.1) for 




3.3.1.4 MRM transition 293.1→249.1 
Three, four and four phenyl mono-oxidative metabolite isomers were generated in rat, 
pig and human liver microsomes, respectively (Table 3-2). Among them, M293-1 
(4.87 min) and M293-5 (5.71 min) were observed in all of the three species. M293-3 
(5.28 min) was only observed in rat and pig liver microsomes, whereas M293-4 (5.44 
min) was only observed in pig and human liver microsomes. Additionally, M293-2 
(5.08 min) with very low abundance was only observed in human liver microsomes 
rather than the other two animal microsomes. The abundances of phenyl 
mono-oxidative metabolites in pig liver microsomes were more significant than those 
in the other two liver microsomes. 
There were two types of EPI (MS/MS) mass spectra with regard to phenyl 
mono-oxidative metabolites. The result indicated that the two types of metabolites 
should be position isomers with single hydroxyl group located at the two different 
phenyl rings. For each type, there were four maximal possibilities regarding the 
specific positions of hydroxyl group on the phenyl ring. The representative mass 
spectrum of one type was the EPI of M293-4 (5.44 min). The proposed fragmentation 
scheme and MS/MS spectrum of this type are shown in Fig. 3-3 (A). Loss of CH3, 
H2O and CO following gain of one H generated the product ion at m/z 278, 275 and 
265, respectively. Loss of CONH generated the product ion at m/z 249. Loss of 
CONCH3 following loss of one H generated the product ion at m/z 234. Loss of both 
CONH and CO following gain of one H generated the product ion at m/z 222. Loss of 
CH3, H2O, CONH and O following gain of one H generated the product ion at m/z 
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201. Subsequent loss of CO at position 2 after the cleavage of the 3,3’ bond generated 
the product ion at m/z 133, which was 16 Da higher than the corresponding product 
ion of meisoindigo at m/z 117, thus indicating hydroxylation had occurred at one of 
the positions 4, 5, 6 and 7. Simultaneous cleavages of 1,8 bond and 3,9 bond 
following loss of one H generated the product ion at m/z 91. The representative of the 
other type was the EPI of M293-5 (5.71 min). The proposed fragmentation scheme 
and MS/MS spectrum of this type are shown in Fig. 3-3 (B). The fragmentations of 
the product ions at m/z 278, 275, 265, 249, 234, 222 and 201 were the same as 
described above. Subsequent loss of CO at position 2’ after the cleavage of the 3,3’ 
bond following gain of one H generated the product ion at m/z 120, which was 16 Da 
higher than the corresponding product ion of meisoindigo at m/z 104, thus indicating 
hydroxylation had occurred at one of the positions 4’, 5’, 6’ and 7’. Simultaneous 
cleavages of 1’,8’ bond and 3’,9’ bond following loss of one H generated the product 
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FIG. 3-3. MS/MS spectra of protonated metabolites at m/z 293 and the proposed 
origin of key product ions. 
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 3.3.1.5 MRM transition 263.1→235.1 
Only one N-demethyl metabolite with retention time of 4.79 min was generated in pig 
and human liver microsomes rather than rat liver microsomes (Table 3-2). The 
abundance of this metabolite in pig liver microsomes was higher than that in the 
human liver microsomes. The proposed fragmentation scheme and EPI (MS/MS) 
spectrum of protonated metabolites at m/z 263 are shown in Fig. 3-4. Loss of H2O 
following gain of one H generated the product ion at m/z 245, and subsequent loss of 
CO generated the product ion at m/z 217. Loss of one or two CO following gain of 
one H generated the product ions at m/z 235 and m/z 207, respectively. Loss of CONH 
following gain of one H generated the product ion at m/z 220. Loss of both CONH 




















































FIG. 3-4. MS/MS spectrum of protonated metabolite at m/z 263 and the proposed 
origin of key product ions. 
 
Therefore, based on the metabolite profiling, four metabolic pathways of meisoindigo 
in the liver microsomes of all three species were proposed as direct 3,3’ double bond 
reduction, reduction followed by N-demethylation, reduction followed by phenyl 
mono-oxidation and direct phenyl mono-oxidation (Fig. 3-5). Among them, direct 3,3’ 
double bond reduction was the major metabolic pathway for all of the three species. 
In addition, direct N-demethylation was proposed as a minor metabolic pathway in 
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FIG. 3-5. Proposed metabolic pathway of meisoindigo in rat, pig, and human liver 
microsomes. Chiral centers are indicated with asterisks. 
 
3.3.2 Metabolic stability 
Metabolic stability of meisoindigo was determined in triplicate at eight time points 
between 5 and 90 min in gender-specific rat, pig and human liver microsomes. Fig. 
3-6 (A through C) shows the phase I metabolic stability for meisoindigo in both 
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genders for rat, pig and human liver microsomes, respectively. The error bars reflect 
the difference of the individual values from the mean. These data suggest that 
meisoindigo underwent a rapid and extensive metabolism in both genders of all three 
species, such that less than 20% of the starting concentration of meisoindigo was 
found to be remaining after 90 min of incubation. Under the same incubation 
conditions, about 11% and 18% of the starting concentration of meisoindigo remained 
in each gender of rat and pig liver microsomes respectively, whereas about 6% 



















































































FIG. 3-6. Metabolic stability profiles for meisoindigo in liver microsomes: rat (A), 
pig (B), and human (C). 
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 The calculated in vitro t1/2 and in vitro CLint values of meisoindigo in gender-specific 
rat, pig and human liver microsomes were listed in Table 3-3, except the in vitro CLint 
values in pig liver microsomes due to the absence of the required physiological 
parameters in the previous literatures for the pigs used in this study. One way ANOVA 
analysis showed that there were no statistically significant differences in the rates of 
meisoindigo metabolism among three species, thus indicating the correlation in the in 
vitro metabolism of meisoindigo in humans and the two preclinical animal species, i.e. 
rats and pigs. Independent two sample t-tests showed that there were no statistically 
significant differences between different genders for each species, suggesting the 
gender effect on the in vitro metabolism of meisoindigo was negligible for rats, pigs 
and humans. 
 
TABLE 3-3. The calculated in vitro t1/2 and in vitro CLint values (Mean ± SD) of 
meisoindigo for the three species with different genders 
Species Gender In vitro t1/2 (min) 
In vitro CLint 
(ml/min/kg) 
Male 29.69 ± 1.11 84.12 ± 3.23 Rat 
Female 30.10 ± 0.46 82.92 ± 1.26 
Male 35.93 ± 4.63 ⎯ Pig Female 37.12 ± 4.28 ⎯ 
Male 22.27 ± 1.36 84.19 ± 5.13 Human Female 23.01 ± 0.64 81.31 ± 2.30 
 
3.3.3 Metabolite formation 
Fig. 3-7 (A through F) shows the formation of two major reductive metabolites of 
meisoindigo as representative in both genders for rat, pig and human liver 
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microsomes, respectively. The error bars reflect the difference of the individual values 
from the mean. The metabolite formation profiles of M279-1 and M279-2 at different 
time points showed similar trends in each of the liver microsomes. All the curves did 
not start ascending from zero peak area at the time point of 0 min with the two 
reductive metabolites, indicating the existence of minute non-enzymatic reduction of 
meisoindigo in the control samples. Besides, M279-2 always showed higher 
abundance than M279-1, which further confirmed that reduction metabolism of 
meisoindigo was stereoselective. Formations of each of the other minor metabolites of 
meisoindigo (Table 3-2) varied with species and were determined as well in triplicate 
































































































































FIG. 3-7. Formation of reduced-meisoindigo metabolites in liver microsomes: male 




This is the first comparative investigation of in vitro phase I interspecies metabolism 
of meisoindigo in rat, pig and human with different genders from both qualitative and 
quantitative aspects. In the present study, rats (rodent animals) were chosen because 
rats express two major cytochrome P450 isoforms that are oligomerically related to 
human CYP3A4, CYP3A1 and CYP3A2 (Nelson et al., 1996). Pigs (nonrodent 
animals) were chosen because CYP3A29 has been identified in the pig according to 
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European Molecular Biology Laboratory/GenBank/DNA Data Bank of Japan 
databank submissions (Jurima-Romet et al., 2000) as an ortholog of human CYP3A4. 
Furthermore, it has been reported that there are similarities between pig and human 
CYP450 metabolizing systems (Anzenbacher et al., 2002; Myers et al., 2001).  
In terms of qualitative analysis, the in vitro metabolic pathways of meisoindigo in rat, 
pig and human liver microsomes were proposed as stereoselective reduction, 
stereoselective reduction followed by N-demethylation, as well as both stereoselective 
and regioselective reduction followed by phenyl mono-oxidation, which were 
consistent with those in male rat liver microsomes reported in Chapter 2. Two more 
novel metabolic pathways were proposed as direct phenyl mono-oxidation in all of the 
three liver microsomes, as well as direct N-demethylation in only pig and human liver 
microsomes. From this point of view, pig might potentially be a better model than rat 
for the assessment of toxicological risks associated with meisoindigo metabolites, at 
least from a metabolic perspective. It was not clear that whether direct phenyl 
mono-oxidation was regioselective or not, whereas direct N-demethylation was 
definitely neither stereoselective nor regioselective since only one metabolite was 
likely to be formed. 
On the other hand, metabolites generated from the respective processes of reduction, 
reduction followed by N-demethylation, and reduction followed by phenyl 
mono-oxidation metabolism of meisoindigo were more evident in rat liver 
microsomes than in the microsomes of the other two species. In contrast, direct 
phenyl mono-oxidation and direct N-demethylation metabolism of meisoindigo were 
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more evident in pig liver microsomes than in rat and human microsomes. In addition, 
the two metabolites undergone reduction followed by phenyl mono-oxidation at 
positions 4, 5, 6 or 7 i.e. M295-6 (4.87 min) and M295-7 (5.05 min), as well as one 
metabolite undergone direct phenyl mono-oxidation i.e. M293-2 (5.08 min) were 
found to be uniquely present in human liver microsome, which implied a proper 
attention to the correlation between human and these two preclinical animal species. 
In terms of semi-quantitative analysis, the metabolic stability and metabolite 
formation of meisoindigo in these three species were determined and plotted, 
respectively. The depletion method, first-order consumption of parent drug 
meisoindigo was monitored in liver microsomal incubations to yield in vitro t1/2 
values, assuming that the substrate concentration (1uM) used is well below the km 
value of all the important metabolizing enzymes involved in the metabolism of 
meisoindigo. The in vitro intrinsic clearance (CLint) values of meisoindigo in 
gender-specific rat and human liver microsomes were calculated accordingly as well. 
Extrapolation of in vivo hepatic clearance from in vitro intrinsic clearance involved 
the use of equations describing the well-stirred or parallel tube liver models of in vivo 
hepatic clearance. One of the underlying assumptions is that oxidative microsomal 
metabolism is the predominant one (Obach et al., 1997). However, the major 
metabolic pathway of meisoindigo is reduction, which does not meet this assumption. 
Thus, the extrapolation of in vivo hepatic clearance could not be performed. 
In addition, statistical analysis showed that there were overall similarities in the 
metabolic stability profiles of meisoindigo in terms of amount of substrate remaining 
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within 90 min of incubation among rat, pig and human. This result exhibited a good 
correlation in the in vitro metabolism of meisoindigo between human and these two 
preclinical animal species, thus providing adequate evidence for the prediction of in 
vitro metabolism of meisoindigo in human from those in rat and pig, as well as the 
decision of appropriate species for toxicology studies. It should be also noted that the 
unique metabolites which are only present in human rather than other preclinical 
animal species must be seriously taken into account in the process of the human 
metabolism prediction using other species. Furthermore, statistical analysis showed 
that there were overall similarities in the metabolic stability profiles of meisoindigo 
between different genders among the three species. These results could lead to a better 
understanding of the gender effect on metabolic profile of meisoindigo among the 
three species, and implied that it might not be necessary to adjust the dosing regimen 
of meisoindigo according to different patient genders for more effective and safer 
therapy of chronic myelogenous leukemia.  
On the other hand, the subtle differences among species could not be fully revealed 
through the determination of the parent disappearance, which was conducted by 
monitoring the decrease of the parent drug from a high initial concentration and thus 
compromising the sensitivity of the measurement. In contrast, the metabolite 
formation was measured against the blank, and thus reliably provided meaningful 
information of relative kinetics comparison of each phase I metabolites of 
meisoindigo in the three species. Considering the signal to noise (S/N) ratios of some 
minor metabolites at certain time points were below 10 though above 3.3, only the 
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formation profiles of the most significant and the most common reductive metabolites 
were included herein. It should be noted that the formation rates of the reductive 
metabolites were not shown in Fig. 3-7 due to absence of the metabolite standards. 
Although the two reductive metabolites have been synthesized, it was found that the 
conversion of M279-1 to M279-2 was likely to take place especially in liquid state, 
which caused difficulty to determine the formation rates accurately. 
In terms of the methodology adopted, the smaller particle size of UFLC and higher 
sensitivity of MRM jointly led to the successful detection of more reductive plus 
phenyl mono-oxidative metabolites at m/z 295 at trace levels with good resolution 
(Fig. 3-1 and Fig. 3-2), as well as new phenyl mono-oxidative metabolites at m/z 293 
and one new N-demethyl metabolite at m/z 263, through filtering out unspecific 
responses in microsomal matrices. Co-eluting metabolites such as M295-6 (4.87 min), 
M295-14 (4.86 min) and M293-1 (4.87 min), were detected individually owing to the 
specificity of their respective MRM transitions. The UFLC coupled with MRM also 
enabled an overall better separation through a broader and shorter gradient elution 
program ranging from 5 % to 95 % within a total run time of 20 min.  
However, the MRM in combination with EPI was unable to detect and identify 
unexpected metabolites as compared to the conventional full MS scan (EMS) in 
combination with MS/MS (EPI), if the MRM transitions only depended on the 
generation through the script in Analyst software to cover the unknown metabolites. 
This disadvantage was improved by addition of possible MRM transitions or removal 
of unlikely MRM transitions based on the knowledge of the metabolic predictions and 
 86
the MS/MS fragmentation pattern prediction, as well as experimental results obtained 
by EMS in combination with EPI reported in Chapter 2. From another point of view, 
the pilot study showed that EMS spectra and UV chromatograms for the three species 
were similar while the minor metabolites were only observed in the rat, suggesting 
that the extent of metabolism in the rat was relative high and thus it was reasonable to 
search out most of the metabolites in the pig and human based on the MRM 
transitions obtained from the experiments with rat microsomes. In addition, MRM 
provided another dimension of relative kinetic information through simultaneous 
quantitative analysis of the parent drug disappearance and metabolite appearance as a 
function of time within one single sample injection. Therefore, integration of MRM 
with conventional metabolic profiling methodology enables a wide range of potential 
transitions to be targeted for metabolite detection and could be a powerful tool to 
provide more comprehensive metabolism information with regard to both qualitative 




                                                                      
CHAPTER 4 
Characterization of metabolites of meisoindigo in rat kidney 
microsomes by HPLC-MS/MS 
                                                                      
4.1 INTRODUCTION 
Although the liver generally plays the major role in drug metabolism (Williams et al., 
1990), drug metabolizing enzymes are also present at other extrahepatic sites. 
Depending on the particular drug involved, extrahepatic organs and/or tissues such as 
small intestine, kidney, lung and colon etc may account for a significant part of 
metabolic clearance of the drug and thus should be considered in the study of drug 
metabolism (De Kanter et al., 2004). For instance, intestinal cytochrome P450 3A and 
3B have been found to catalyze hydroxylation of testosterone (Van de Kerkhof et al., 
2007). Another example is that renal cytochrome P450 2C23, A8 and 4A2 have been 
shown to catalyze O-dealkylation of 7-ethoxy-coumarin (Imaoka et al., 1990). 
The in vitro metabolite identification of meisoindigo in rat liver microsomes has been 
carried out by either HPLC (Peng and Wang, 1990) or LC-MS/MS in the previous 
studies discussed in Chapter 2 and 3. Five metabolic pathways of meisoindigo in male 
rat liver microsomes were proposed as direct 3,3’ double bond reduction, reduction 
followed by N-demethylation, reduction followed by phenyl mono-oxidation, direct 
phenyl mono-oxidation, as well as direct N-demethylation. It was also reported that, 
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after oral administration of 3H-meisoindigo, the excretion of radioactivity in the 48 h 
feces was about 17.3 %, whereas about 34.3 % was present in the 48 h urine (Ji et al., 
1991). It is not clear, in addition to liver, whether kidney is also involved in the 
metabolism of meisoindigo. Furthermore, information relevant to extrahepatic 
metabolism of meisoindigo, especially in kidney, is absent so far. Therefore, the 
objective of the present study in Chapter 4 was to qualitatively and quantitatively 
investigate the in vitro metabolism of meisoindigo in rat kidney microsomes of 
different genders by HPLC-MS/MS, in terms of metabolite identification, metabolic 
stability, metabolite formation and gender effect. Kidney microsomes were used as the 
in vitro metabolic system in this study, as they contain critical drug metabolizing 
enzymes such as the cytochrome P450, cysteine conjugateβ-lyase, epoxide hydrolyase, 
ketone reductase, sulfotransferase (James et al., 1998).  
4.2 MATERIALS AND METHODS 
4.2.1 Chemicals 
All reagents were of analytical grade and used without further purification. Tris-HCl 
buffer, sucrose, calcium chloride, β-nucleotinamide adenine dinucleotide phosphate 
(β-NADPH), formic acid, bovine serum albumin (BSA) and bradford reagent were 
purchased from Sigma Chemical Co. (St. Louis, Mo, USA). Meisoindigo was 
provided by Institute of Materia Medica, Chinese Academy of Medical Sciences and 
Peking Union Medical College (Beijing, China). HPLC grade methanol and 
acetonitrile were purchased from Fisher Scientific Co. (Fair Lawn, NY, USA). 
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Milli-Q water was obtained from a Millipore water purification system (Billerica, MA, 
USA) and used to prepare buffer solutions and other aqueous solutions. 
4.2.2 Preparation of rat kidney microsomes 
Pooled rat kidney microsomes were prepared according to the method reported 
previously (Gibson and Skett, 1994). Three male and three female Sprague-Dawley 
(SD) rats were obtained from Animal Holding Unit, National University of Singapore 
and were sacrificed by CO2 asphyxiation after a 24-h fasting period. The kidneys were 
excised, pooled according to genders and homogenized with a four-fold volume of 
0.25 M sucrose solution to make a 20 % homogenate. The post-mitochondrial 
supernatant was obtained by centrifuging the kidney homogenate at the speed of 
12500 g for 15 minutes at 2 oC. Microsomal fractions were then prepared by mixing 
the supernatant with one-tenth volume of CaCl2 solution before centrifuging at the 
speed of 27000 g for 15 minutes at 2 oC. The extracted kidney microsomes were 
suspended in 0.1 M Tris-HCl buffer (PH 7.4) and stored at -80 oC before use. The 
microsomal protein contents were determined by Bradford assay method, using BSA 
as the standard protein (Bradford, 1976). 
4.2.3 Metabolite identification  
4.2.3.1 Microsomal incubation 
Meisoindigo stock solution was first added to 0.1 M Tris-HCl buffer before adding the 
male or female rat kidney microsomes. The mixture was shaken for 3 min for 
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equilibration in a shaking water bath at 37 ℃. The incubation was then initiated by 
adding β-NADPH solution. The final concentrations of meisoindigo, β-NADPH and 
the microsomal protein were 50 μM, 1 mM and 1 mg/mL, respectively in a typical 
incubation mixture (1 mL). Two sets of samples of the respective male and female rat 
kidney microsomes were prepared. For each set, an appropriate blank was also 
prepared by replacing meisoindigo with Milli-Q water while a negative control was 
prepared with no meisoindigo added until the end of the complete incubation. After 
one-hour incubation, 1 mL of ice-cold acetonitrile was added to quench the reaction. 
The samples were subsequently vortex-mixed and centrifuged at 14000 rpm for 15 
min. The supernatant was transferred into clean vials for LC-MS/MS analysis. 
4.2.3.2 Chromatography and mass spectrometry conditions 
The blank, negative control and samples were analyzed using a LC-MS/MS system 
consisting of a series 1200 HPLC (Agilent Technologies, Palo Alto, CA, USA) with a 
Q TRAP™ 3200 hybrid triple quadrupole linear ion trap mass spectrometer from 
Applied Biosystems / MDS Sciex (Concord, Ontario, Canada). Chromatographic 
separations were performed on a Luna C18 column (150 mm × 2.00 mm i.d., 5 μm) 
(Phenomenex, Torrance, CA, USA) with a guard cartridge. The injection volume and 
column temperature were 5 µl and 25 oC, respectively. The mobile phases consisted of 
0.1 % formic acid in water (solvent A) and acetonitrile (solvent B). The gradient 
elution was set at a flow rate of 300 µL/min. The optimized linear gradient elution 
conditions were: 5 % to 95 % B over 25 min, followed by an isocratic hold at 95 % B 
for another 5 min. At 30 min, B was returned to 5 % in 1 min and the column was 
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equilibrated for 19 min before the next injection. The total run time was 50 min. 
During LC-MS/MS analysis, up to 3 min of the initial flow was diverted away from 
the mass spectrometer before evaluation of metabolites. The mass spectrometer was 
operated in the positive ion mode with a TurboIonSpray source. Mass spectrometry 
optimization was achieved by adjustments of both the compound dependent 
parameters (declustering potential: 50.0 V, entrance potential: 10.0 V, collision energy: 
40.0 eV) and source dependent parameters (curtain gas: 20.0 arbitrary units, collision 
gas: high, ion spray voltage: 5500 V, source temperature: 450oC, ion source gas 1: 30 
arbitrary units, ion source gas 2: 40 arbitrary units). Enhanced Q3 Single MS (EMS) 
was employed to do a full scan with a range of m/z 50-400 to capture all the ions 
produced from the negative control and sample. Enhanced Product Ion (EPI) was 
subsequently used to do in depth scans of specific ions of interest, based on the EMS 
comparison of negative control and sample, in order to get their fragmentation 
patterns. The corresponding EPI of potential metabolites were compared with that of 
meisoindigo to investigate the fragmentation patterns and obtain information on the 
metabolite structures. In addition, Multiple Reaction Monitoring (MRM) was 
included to compare the signal intensity of the metabolites peaks in both negative 
control and sample to identify the minor metabolites, as MRM is the most sensitive 
scan type. A list of MRM transitions, including 279.1→147.1 for hydrogenation, 
265.1→133.1 for hydrogenation followed by demethylation, 295.1→163.1 and 
295.1→147.1 for hydrogenation followed by oxidation, 293.1→249.1 for oxidation, 
309.1→265.1 for dioxidation, 263.1→235.1 for demethylation, 311.1→178.1 for 
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hydrogenation followed by dioxidation, was used to cover the most common phase I 
biotransformation reactions of meisoindigo. The Q1 and Q3 values were based on the 
phase I biotransformation prediction of meisoindigo by MetaboliteID 1.4 software 
from Applied Biosystems / MDS Sciex as well as the previous results of meisoindigo 
and its phase I metabolites in rat liver microsomes in Chapter 2. The ionization 
parameters were the same as described above except declustering potential and 
collision energy were adjusted to 60.0 V and 30.0 eV, respectively. The dwell time of 
each MRM transition was 150 msec. The associated EPI scans were subsequently 
conducted to obtain more information on the minor metabolite structures. The HPLC 
system and the mass spectrometer were controlled by Analyst™ 1.4.2 software from 
Applied Biosystems / MDS Sciex. 
4.2.4 Metabolic stability and metabolite formation 
4.2.4.1 Microsomal incubation 
10 µL of 1 mM meisoindigo stock solution in methanol was first added to 0.1 M 
Tris-HCl buffer before adding the male or female rat kidney microsomes. The mixture 
was shaken for 3 min for equilibration in a shaking water bath at 37℃. The incubation 
was then initiated by adding β-NADPH solution. The final concentrations of 
meisoindigo, β-NADPH and the microsomal protein were 1 μM, 1 mM and 0.5 
mg/mL, respectively in a typical incubation mixture (1mL). Three sets of samples 
were prepared for both male and female kidney microsomes. Aliquots of 100 µL of 
the incubation sample mixtures were collected at 5, 10, 20, 30, 40, 50, 60, 90 and 120 
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minute with the addition of an equal volume of ice-cold acetonitrile to terminate the 
reaction. For each kidney microsomes, three negative controls were prepared with no 
meisoindigo added until the end of the complete incubation and set as the 0 minute 
aliquots. The samples were subsequently vortex-mixed and centrifuged at 14000 rpm 
for 15 min. The supernatant was transferred into clean vials for LC-MS/MS analysis. 
4.2.4.2 Chromatography and mass spectrometry conditions 
Metabolic stability and metabolite formation of meisoindigo were conducted on the 
same LC-MS/MS for metabolite identification with identical chromatographic 
conditions. MRM was employed to monitor the decline of the parent drug as well as 
to quantify the amount of major metabolites produced simultaneously. MRM 
transition 277.1→234.2 was selected for the parent drug quantification and 
279.1→147.1 was selected for the major metabolite quantification in positive ion 
mode. The ionization parameters were the same as described above for metabolite 
identification, except declustering potential and collision energy were 66.0 V and 45.0 
eV for 277.1→234.2, 60.0 V and 30.0 eV for 279.1→147.1, respectively. 
4.2.4.3 Data analysis 
In the determination of the in vitro half-life (t1/2), the concentrations of meisoindigo at 
different time points were converted to parent remaining percentages, using the 
concentration at 0 min as 100 %. The parent remaining percentages of meisoindigo 
were plotted against the microsomal incubation time by Microsoft Excel. Data points 
were the average of three measurements with standard deviations as the error bars. 
The in vitro t1/2 (in units of min) was calculated from the slope of the linear regression 
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of the natural logarithm of the parent remaining percentage versus incubation time 
according to the following formula: t1/2 =ln2/slope (Obach et al., 1997; Obach, 1999). 
Peak areas of metabolites were also calculated and plotted against the microsomal 
incubation time by Microsoft Excel. Data points were the average of three 
measurements with standard deviations as the error bars. Statistical comparisons in 
the rates of meisoindigo metabolism between two genders were made using 
independent two sample t-tests by GraphPad Prism 4 software. Differences were 
considered as statistically significant when p value was less than 0.05. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Metabolite identification 
The total ion chromatograms of the blank, negative control and sample in the male rat 
kidney microsomes showed that the peak of meisoindigo was present with relatively 
high intensity in the negative control and relatively low intensity in the sample while 
absent in the blank, indicating the occurrence of the metabolism of meisoindigo and 
no interference from microsomal matrix on the detection of meisoindigo. Comparison 
of EMS for both the negative control and sample ranging from the retention time of 3 
min to 24 min showed two potential metabolites at m/z 301 which existed in the 
sample instead of the negative control and were eluted with shorter retention times as 
compared to that of meisoindigo. Fig. 4-1 showed the extracted ion chromatograms of 
EMS at m/z 301 (actually sodium adduct of metabolites) for negative control and 
sample in male rat kidney microsomes. This result clearly illustrated two peaks with 
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retention times of 17.26 and 18.12 minutes only in the sample rather than the control, 
suggesting that they were potential metabolites. However, no potential metabolites 
were detected by the same full scan in female rat kidney microsomes due to their trace 
level. This situation was improved by MRM which will be discussed later. 
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FIG. 4-1. Extracted ion chromatograms of EMS from m/z 301 to 301.5 for control (A) 
and sample (B) in male rat kidney microsomes. 
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Both of the subsequent EPI (MS/MS) mass spectra (Fig. 4-2) of the two potential 
metabolites at m/z 279 in male rat kidney microsomes were identical, indicating these 
two metabolites could be stereoisomers. When compared with the MS/MS spectrum 
of meisoindigo, the fragmentation patterns were similar after calculating the m/z 
difference between each product ion and the molecular ion, which further confirmed 
that these two peaks were structurally related to meisoindigo and should be 
metabolites of meisoindigo. The fragmentation scheme of protonated metabolites at 
m/z 279 was proposed that cleavage of the 3,3’ bond generated the most abundant 
product ions at m/z 147, as well as m/z 133 which was 1 Da higher than the 
corresponding product ion of meisoindigo at m/z 132, thus indicating the presence of 
3,3’ single bond resulting from double bond reduction. The structures of product ions 
at m/z 147 and m/z 133 were shown in Fig. 4-2, respectively. 
 +EPI (279.10) CE (35) CES (5): 18.929 to 19.229 min from Sample 3 (279 male kidney sample 1) of formal EPI HCOOH.wiff (Turbo Spray) Max. 3.2e4 cps.
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FIG. 4-2. EPI mass spectra of protonated M1+M2 and M3+M4 at m/z 279.1 for male 
rat kidney microsomal sample. 
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 Since 3,3’ double bond reduction caused the generation of two chiral carbon centers 
located in position 3 and 3’, four stereoisomers i.e. M1, M2, M3, M4 at m/z 279 could 
exist with possible absolute configurations of (3-R, 3’-R), (3-S, 3’-S), (3-R, 3’-S), 
(3-S, 3’-R). Among them, M1 and M2, M3 and M4 were assumed as enantiomers of 
each other respectively. The peak with retention time of 17.26 min was postulated to 
be a combination of M1 and M2, whereas the other peak with retention time of 18.12 
min was postulated to be a combination of M3 and M4 (Fig. 4-1). Similar 
phenomenon was also observed from the incubation sample of meisoindigo in male 
rat liver microsomes in Chapter 2. Comparison of the retention times of these two 
potential metabolites from liver and kidney microsomes showed that they could be the 
same compounds. Besides, these two potential metabolites from liver and kidney 
microsomes showed the same EPI (MS/MS) mass spectra. Therefore, based on the 
results from metabolism of meisoindigo in male rat liver microsomes in Chapter 2, 
M1+M2 generated in male rat kidney microsomes was a pair of (3-R, 3’-R) and (3-S, 
3’-S) reduced-meisoindigo enantiomers with two hydrogens located at the same side 
of 3,3’-single bond, whereas M3+M4 was another pair of (3-R, 3’-S) and (3-S, 3’-R) 
enantiomers with two hydrogens located at the opposite sides. Furthermore, the 
different abundance of M1+M2 and M3+M4 shown in Fig. 4-1 suggested that the 
reductive metabolism of meisoindigo was stereoselective. 
On the other hand, the results of MRM scan (Fig. 4-3 and 4-4) showed that significant 
metabolites were searched out with only two MRM transitions i.e. 279.1→147.1 for 
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hydrogenation, 293.1→249.1 for oxidation, respectively. Fig. 4-3 showed that two 
reductive metabolites with MRM transition 279.1→147.1 were generated in female 
rat kidney microsomes (Fig. 4-3 (B)), while they happened to be the two degradation 
products of meisoindigo in kidney microsomal matrices (Fig. 4-3 (A)). Metabolite 
profiles in male rat kidney microsomes were found to be similar as those in female 
microsomes while showed higher peak abundances. Subsequent EPI results at m/z 
279 for both male and female rat kidney microsomes were similar as shown in Fig. 
4-2. Fig. 4-4 showed the comparison of metabolite profiles with MRM transition 
293.1→249.1 in male and female rat kidney microsomes. Three mono-oxidative 
metabolite isomers were generated in male rat kidney microsomes (Fig. 4-4 (A)) 
while only two metabolite isomers were generated in female microsomes (Fig. 4-4 
(B)). Besides, higher peak intensity was found in the male microsomes as compared 
to that in the female microsomes (Fig. 4-4). These results indicated that more 
mono-oxidative metabolites isomers were produced in male rat kidney microsomes. 
Unfortunately, subsequent EPI spectra at m/z 293 were not able to be obtained due to 
trace amount of these minor metabolites. It should be also noted that, due to similar 
chromatographic behaviors of mono-oxidative metabolite isomers, it was possible that 
the most abundant peak in Fig. 4-4 (A) and (B) comprised more than one component 
showing the same MRM transition. 
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FIG. 4-3. Extracted ion chromatograms of MRM transition 279.1→147.1 for control 
(A) and sample (B) in female rat kidney microsomes. 
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FIG. 4-4. Extracted ion chromatograms of MRM transition 293.1→249.1 for samples 
in male (A) and female (B) rat kidney microsomes. 
 
Mono-oxidation metabolism of meisoindigo led to two different types of position 
isomers, namely M293 with single hydroxyl group on the left phenyl ring and M293 
with single hydroxyl group on the right phenyl ring. For each type, there were four 
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maximal possibilities regarding the specific positions of hydroxyl group on the phenyl 
ring. In addition, the chromatographic peak areas shown in Fig. 4-4 suggested that the 
mono-oxidation metabolism of meisoindigo was regioselective. 
 
Table 4-1. HPLC-QTRAP retention times and mass spectra properties for 
meisoindigo and its in vitro metabolites in male rat kidney microsomes. 
 Description [M+H]+ Retention time (min) m/z of major product ions 












NA: not applicable. 
 
Table 4-1 summarized the metabolites of meisoindigo generated in male rat kidney 
microsomes after incubation for 60 min with substrate concentration of 50 uM. Based 
on the metabolite profiling, the major metabolic pathway of meisoindigo in the rat 
kidney microsomes was proposed as stereoselective 3,3’ double bond reduction, 
whereas the minor metabolic pathway was proposed as regioselective phenyl 
mono-oxidation (Fig. 4-5). These two metabolic pathways were partially consistent 
with those metabolic pathways in rat liver microsomes reported in Chapter 2. Rat 
kidney microsomes did not form any metabolites that were not produced by liver 
microsomes. However, meisoindigo was metabolized in rat kidney microsomes to a 
much less extent as compared to rat liver microsomes. In addition, investigation on 
metabolism of meisoindigo in the rat small intestine microsomes showed that the 
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same reductive metabolites were produced as well, with peak intensities significantly 
lower than those from rat kidney microsomes. This result gave more evidence that 
metabolism of meisoindigo was more extensive in the rat kidney microsomes than in 

























































FIG. 4-5. Proposed metabolic pathways of meisoindigo in both male and female rat 
kidney microsomes, with the major reduction pathway producing four stereoisomers 
of reduced-meisoindigo and the minor oxidation pathway producing two types of 
position isomers of mono-hydroxyl-meisoindigo. 
 
In terms of the methodology adopted for metabolite identification, the substrate 
concentration was set at 50 µM, the upper limit of typical concentration range (Chen 
et al., 2007), in order to achieve maximum metabolism to facilitate searching for the 
most number of possible types of metabolites formed. Furthermore, the application of 
MRM with higher sensitivity led to the successful detection of new phenyl 
mono-oxidative metabolites at m/z 293 at trace levels (Fig. 4-4), through filtering out 
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unspecific responses in microsomal matrices. However, the MRM in combination 
with EPI was unable to detect and identify unexpected metabolites as compared to the 
conventional full MS scan (EMS) in combination with MS/MS (EPI), if the MRM 
transitions only depended on the generation through the script in AnalystTM software 
to cover the unknown metabolites. This disadvantage was improved by addition of 
possible MRM transitions or removal of unlikely MRM transitions based on the 
knowledge of the metabolic predictions and the MS/MS fragmentation pattern 
prediction, as well as experimental results obtained by EMS in combination with EPI 
reported in Chapter 2. Therefore, integration of MRM with conventional metabolic 
profiling methodology enables a wide range of potential transitions to be targeted for 
metabolite detection and could be a powerful tool to provide more comprehensive 
metabolism information of the drug. 
4.3.2 Metabolic stability and metabolite formation 
Metabolic stability of meisoindigo was determined in triplicate at nine time points 
between 5 and 120 min in male and female rat kidney microsomes respectively, as 
shown in Fig. 4-6. These results showed that the concentrations of meisoindigo in 
both male and female rat kidney microsomes dropped sharply in the first 10 minutes 
of incubation, indicating that most of the metabolites were produced during this 
period. Subsequently, there was a slow decline in each case amidst some slight 
fluctuations. This provided clear evidence that meisoindigo underwent an extensive 
metabolism in both genders of rat kidney microsomes, such that less than 30% of the 
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starting concentration of meisoindigo was found to be remaining after 120 min of 
incubation. Under the same incubation conditions, about 19% of the starting 
concentration of meisoindigo remained in male rat kidney microsomes, whereas about 
























FIG. 4-6. Metabolic stability profile of meisoindigo in male and female rat kidney 
microsomes. 
 
The depletion method, first-order consumption of parent drug meisoindigo was 
monitored in rat kidney microsomal incubations to yield in vitro t1/2 values, assuming 
that the substrate concentration (1uM) used is well below the km value of all the 
important enzymes involved. The microsomal protein concentration used (0.5 mg/mL) 
was also lower than the concentration used for metabolite identification (1.0 mg/mL), 
to prevent the effect caused by microsomal protein binding. The calculated in vitro t1/2 
values of meisoindigo in male and female rat kidney microsomes were 107.8 ± 17.0 
min and 130.0 ± 12.9 min, respectively. The calculation of in vitro intrinsic clearance 
(CLint) values was not conducted due to the absence of required physiological 
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parameters for rat kidney reported in the previous literatures.  
Independent two sample t-tests showed that there were no statistically significant 
differences between different genders in the rates of meisoindigo metabolism, thus 
suggesting the gender effect on the in vitro metabolism of meisoindigo in rat kidney 
microsomes was negligible. These results could lead to a better understanding of the 
gender effect on metabolic profile of meisoindigo, and implied that it might not be 
necessary to adjust the dosing regimen of meisoindigo according to different patient 
genders for more effective and safer therapy of chronic myelogenous leukemia, 
particularly for patients with renal impairment. 
The metabolite formation study was based on a semi-quantification method because 
no standards of metabolites were available for the full method development and 
validation. Fig. 4-7 (A) and (B) showed the peak area-time profiles of reductive 
metabolites of meisoindigo in male and female rat kidney microsomes, respectively. 
The metabolite formation profiles of M1+M2 and M3+M4 at different time points 
exhibited similar trends in both male and female the rat kidney microsomes, with a 
sharp rise within the initial 5 min followed by a slight increase within the rest of time 
till 120 min. Besides, M3+M4 always showed higher abundance than M1+M2, which 
indicated that reduction metabolism of meisoindigo in rat kidney was stereoselective. 
It was also observed that the intensity of metabolites produced in the male rat kidney 
microsomes was slightly higher than that in the female rat kidney microsomes. 
Formations of each of the other minor metabolites of meisoindigo, i.e. M293 at m/z 
293 found under the substrate concentration of 50uM shown in Fig. 4-4, could not be 
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detected due to low signal to noise ratios caused by the trace amounts produced under 












































FIG. 4-7. Formation of reductive metabolites of meisoindigo in male (A) and female 
(B) rat kidney microsomes. 
 
From another point of view, the subtle differences between genders could not be fully 
revealed through the determination of the parent disappearance, which was conducted 
by monitoring the decrease of the parent drug from a high initial concentration and 
thus compromising the sensitivity of the measurement. By contrast, the metabolite 
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formation was measured against the blank, and thus reliably provided meaningful 
information of relative kinetics comparison of reductive metabolites of meisoindigo 
for both of the two genders.  
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CHAPTER 5 
Identification of circulatory and excretory metabolites of 
meisoindigo in rat plasma, urine and feces by HPLC-MS/MS 
                                                                      
5.1 INTRODUCTION 
Although the in vitro metabolic profiles of meisoindigo have been investigated in rat, 
pig and human respectively within Chapters 2 and 3, the in vivo metabolic fate of 
meisoindigo remains to be fully elucidated. Considering both rat and pig form most of 
the major in vitro metabolites identified in humans in Chapter 3, these two preclinical 
animal species could be good models used for pre-clinical safety evaluation of 
meisoindigo from a metabolic perspective. Due to the difficulty in accessing the 
plasma, urine and feces from pig, the in vivo metabolism study in this thesis is only 
restricted to rat, the most common rodent species used in pre-clinical tests. On the 
other hand, results of in vitro and in vivo correlation could be used to predict in vivo 
metabolism from in vitro metabolism before more extensive trials on living animals or 
humans. 
Therefore, in order to gain an understanding of the in vivo metabolism of meisoindigo 
in rat, the objectives of the study in Chapter 5 were to qualitatively identify the 
circulatory and excretory metabolites of meisoindigo in rat plasma, urine and feces. A 
single dose of meisoindigo was orally administered to male SD rats at 10 mg/kg body 
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weight. The plasma, urine and feces were collected for metabolites profiling and 
identification. The metabolites were analyzed on reverse-phase HPLC-MS/MS, and 
where possible, the proposed structures were supported by comparisons of their 
HPLC retention times and MS/MS spectra with those in vitro metabolites reported in 
Chapters 2 and 3. The blanks collected predose served as controls for determining 
endogenous and non–drug-related ions observed within respective matrices or their 
extracts by LC/MS/MS. In terms of methodology, as is discussed in Chapters 3 and 4, 
integration of MRM with conventional metabolic profiling methodology, namely full 
MS scan (EMS) followed by MS/MS (EPI), enabled a wide range of potential 
transitions to be targeted for metabolite detection and thus was adopted herein. 
5.2 MATERIALS AND METHODS 
5.2.1 Chemicals 
All reagents were of analytical grade and used without further purification. Sodium 
carboxymethyl cellulose (CMC-Na) and formic acid were purchased from Sigma 
Chemical Co. (St. Louis, Mo, USA). Meisoindigo was provided by Institute of 
Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical 
College (Beijing, China). HPLC grade methanol and acetonitrile were purchased from 
Fisher Scientific Co. (Fair Lawn, NY, USA). Milli-Q water was obtained from a 
Millipore water purification system (Billerica, MA, USA) and used to prepare buffer 
solutions and other aqueous solutions. 
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5.2.2 Rat plasma, urine, feces collection and sample preparation 
Three healthy male Sprague–Dawley (SD) rats (7–8 weeks of age, average 250 g) 
were purchased from Animal Holding Unit, National University of Singapore. They 
were provided with a standard diet and water ad libitum. The room was kept on a 
12/12-h light/dark cycle at a temperature of 23 ± 1 oC and relative humidity of 50 ± 
10 %. At least one week of acclimatization period was allowed for the rats prior to 
drug administration. The rats were fasted 12 h prior to administration of the dose and 
were fed 12 h after the dose. The dose was formulated in a mixture of meisoindigo 
suspended in 1% sodium carboxymethyl cellulose (CMC-Na) solution at a target 
concentration of 3.75 mg/ml. The rats received meisoindigo solution by gavage 
administration with a single dosage of 10 mg/kg body weight. 
Blood samples were collected in heparinized tubes via caudal vein predose and at 1, 2, 
3, 4, 5, 6, 8, 10 and 24 h postdose for the identification of circulatory metabolites. 
Blood samples were centrifuged at 6000 rpm for 10 min to obtain the plasma. Plasma 
were transferred to clean tubes and stored at -80 °C until analysis. Blank plasma was 
harvested from predose blood samples. For sample preparation, rat plasma obtained 
was diluted with 3 volumes of acetonitrile. The mixture was then centrifuged, and the 
supernatants from each subject were pooled and transferred to a clean tube for 
LC-MS/MS analysis. 
Another group of rats (n = 3) was housed individually in metabolic cages and dosed 
for the identification of excretory metabolites. Urine and feces predose samples i.e. 
blanks were collected at the end of interval of 0–24 h after a 12-h fasting period. 
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Urine and feces postdose samples were collected into clean containers over 24-h 
intervals up to 168 h postdose and stored frozen at -80 °C until analysis. The total 
volume of the urine and total weight of feces for each 24-h intervals were recorded 
after each collection.  
Urine samples from each subject were pooled proportional to the volumes of urine 
within the sampling period. The pooled urine samples were then centrifuged at 6000 
rpm for 15 min to remove particulate materials, and the supernatants were directly 
injected onto the HPLC column for LC-MS/MS analysis without further purification. 
The urine predose samples from each subject were pooled and centrifuged as 
described above. 
Feces samples were added with H2O (3 ml/g feces) and mixed to generate the fecal 
homogenates. The fecal homogenates were pooled proportional to the weights of 
feces within the sampling period. The aliquots of pooled fecal homogenates were 
suspended in acetonitrile (3 ml/g homogenate). Suspensions were sonicated for 30 
min, vortex-mixed and centrifuged at 6000 rpm for 15 min. Then the supernatant was 
transferred to clean tubes, and the residues were further extracted for another two 
times with acetonitrile. The combined supernatants were evaporated to dryness under 
N2 stream at 35 °C in a TurboVap LV evaporator (Caliper Life Sciences, Hopkinton, 
MA, USA), and the residues were reconstituted in acetonitrile and H2O (1:1) for 
LC-MS/MS analysis. The feces predose samples from each subject were pooled and 
extracted as described above. 
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5.2.3 Chromatography and mass spectrometry conditions for rat plasma and feces 
Both predose and postdose samples were analyzed on a Q TRAP™ 2000 LC-MS/MS 
system from Applied Biosystems / MDS Sciex (Concord, Ontario, Canada) coupled to 
an Agilent 1100 HPLC system (Agilent Technologies, Palo Alto, CA, USA). The 
injection volume was 5 μL. Separations were accomplished on a Agilent hypersil 
ODS column (100 ×2.1 mm, 5 μm) (Agilent Technologies, Palo Alto, CA, USA) with 
a guard cartridge at ambient temperature of about 25 ℃. The mobile phase consisted 
of 10 mM ammonium acetate in water (solvent A) and methanol (solvent B) and was 
delivered at a flow rate of 0.2 mL/min. The linear gradient elution program was as 
follows: 20% to 100% B over 30 min, followed by an isocratic hold at 100 % B for 
another 5 min. At 35 min, B was returned to 20% in 1 min and the column was 
equilibrated for 14 min before the next injection. The total run time was 50 min. 
During LC-MS/MS analysis, up to 3 min of the initial flow was diverted away from 
the mass spectrometer before evaluation of metabolites. The mass spectrometer was 
operated in the positive ion mode with a TurboIonSpray source. Mass spectrometry 
optimization was achieved by adjustments of both the compound dependent 
parameters (declustering potential: 26.0 V, entrance potential: 10.0 V, collision energy: 
10.0 eV) and source dependent parameters (curtain gas: 30.0 arbitrary units, collision 
gas: high, ion spray voltage: 5500 V, source temperature: 300 oC, ion source gas 1: 50 
arbitrary units, ion source gas 2: 60 arbitrary units). Enhanced Q3 Single MS (EMS) 
was employed to do a full scan with a range of m/z 50-350 to capture all the ions 
produced from the predose and postdose samples. Enhanced Product Ion (EPI) was 
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subsequently used to do in depth scans of specific ions of interest, based on the EMS 
comparison of predose and postdose samples, in order to get their fragmentation 
patterns. The corresponding EPI of potential metabolites were compared with that of 
meisoindigo to investigate the fragmentation patterns and obtain information on the 
metabolite structures. The mass spectrometer and the HPLC system were controlled 
by Analyst 1.4.1 software from Applied Biosystems / MDS Sciex. 
Multiple reaction monitoring (MRM) was included to compare the signal intensity of 
the metabolites peaks in both predose and postdose samples to identify the minor 
metabolites, as MRM is the most sensitive scan type. The predose and postdose 
samples were analyzed using a LC-MS/MS system consisting of a series 1200 HPLC 
(Agilent Technologies, Palo Alto, CA, USA) with a Q TRAP™ 3200 hybrid triple 
quadrupole linear ion trap mass spectrometer from Applied Biosystems / MDS Sciex 
(Concord, Ontario, Canada). Chromatographic separations for rat plasma were 
performed on a Luna C18 column (150 mm × 2.00 mm i.d., 5 μm) (Phenomenex, 
Torrance, CA, USA) with a guard cartridge. Chromatographic separations for rat feces 
were accomplished on a Agilent hypersil ODS column (100 ×2.1 mm, 5 μm) (Agilent 
Technologies, Palo Alto, CA, USA) with a guard cartridge. The injection volume and 
column temperature were 5 µl and 25 oC, respectively. The mobile phases consisted of 
0.1 % formic acid in water (solvent A) and acetonitrile (solvent B). The gradient 
elution was set at a flow rate of 0.3 mL/min. The optimized linear gradient elution 
conditions were: 5 % to 95 % B over 25 min, followed by an isocratic hold at 95 % B 
for another 5 min. At 30 min, B was returned to 5 % in 1 min and the column was 
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equilibrated for 19 min before the next injection. The total run time was 50 min. The 
mass spectrometer was operated in the positive ion mode with a TurboIonSpray 
source. A list of 9 MRM transitions with the addition of parent drug in Table 5-1 was 
used to cover the most common phase I biotransformation reactions of meisoindigo. 
The Q1, Q3, declustering potential (DP), and collision energy (CE) values were based 
on the phase I biotransformation prediction of meisoindigo by MetaboliteID 1.4 
software from Applied Biosystems / MDS Sciex as well as the previous results of 
meisoindigo and its phase I metabolites in rat liver microsomes in Chapter 2. The 
other ionization parameters were as follows: curtain gas (CUR), 20 (arbitrary units); 
ion source gas 1 (GS1), 40 (arbitrary units); ion source gas 2 (GS2), 50 (arbitrary 
units); source temperature (TEM), 550 oC; entrance potential (EP), 10 V. The dwell 
time of each MRM transition was 150 msec. The HPLC system and the mass 
spectrometer were controlled by Analyst™ 1.4.2 software from Applied Biosystems / 
MDS Sciex. 
 
TABLE 5-1. MRM transition parameters for meisoindigo and its metabolites in rat 













Parent 0 277.1 234.2 66 45 
Hydrogenation 2 279.1 147.1 61 30 
Hydrogenation + demethylation -12 265.1 133.1 60 30 
Hydrogenation + oxidation 18 295.1 163.1 60 30 
Hydrogenation + oxidation 18 295.1 147.1 60 30 
Oxidation 16 293.1 249.1 60 40 
Dioxidation 32 309.1 265.1 60 40 
Demethylation -14 263.1 235.1 60 40 
Hydrogenation + dioxidation 34 311.1 178.1 60 30 
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5.2.4 Chromatography and mass spectrometry conditions for rat urine 
Both rat urine predose and postdose samples were analyzed on a Q TRAP™ 2000 
LC-MS/MS system from Applied Biosystems / MDS Sciex (Concord, Ontario, 
Canada) coupled to an Agilent 1100 HPLC system (Agilent Technologies, Palo Alto, 
CA, USA). The injection volume was 5 μL. Separations were accomplished on a 
Agilent hypersil ODS column (100 ×2.1 mm, 5 μm) (Agilent Technologies, Palo Alto, 
CA, USA) with a guard cartridge at ambient temperature of about 25 ℃. The mobile 
phase consisted of 10mM ammonium acetate in water (solvent A) and methanol 
(solvent B) and was delivered at a flow rate of 0.2 mL/min. The linear gradient 
elution program was as follows: 1 % to 20 % B over the initial 20 min and 20 % to 
100 % B over the subsequent 20 min, followed by an isocratic hold at 100 % B for 
another 5 min. At 45 min, B was returned to 1 % in 1 min and the column was 
equilibrated for 14 min before the next injection. The total run time was 60 min. The 
mass spectrometer was operated in the positive ion mode with a TurboIonSpray 
source. Mass spectrometry optimization was achieved by adjustments of both the 
compound dependent parameters (declustering potential: 26.0 V, entrance potential: 
10.0 V, collision energy: 10.0 eV) and source dependent parameters (curtain gas: 30.0 
arbitrary units, collision gas: high, ion spray voltage: 5500 V, source temperature: 
300oC, ion source gas 1: 50 arbitrary units, ion source gas 2: 60 arbitrary units). 
Enhanced Q3 Single MS (EMS) was employed to do a full scan with a range of m/z 
50-1200 to capture all the ions produced from the predose and postdose samples. 
Enhanced Product Ion (EPI) was subsequently used to do in depth scans of specific 
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ions of interest, based on the EMS comparison of predose and postdose samples, in 
order to get their fragmentation patterns. The corresponding EPI of potential 
metabolites were compared with that of meisoindigo to investigate the fragmentation 
patterns and obtain information on the metabolite structures. The mass spectrometer 
and the HPLC system were controlled by Analyst 1.4.1 software from Applied 
Biosystems / MDS Sciex. 
Multiple reaction monitoring (MRM) was included to compare the signal intensity of 
the metabolites peaks in both predose and postdose samples to identify the minor 
metabolites, as MRM is the most sensitive scan type. The rat urine predose and 
postdose samples were analyzed using a LC-MS/MS system consisting of a series 
1200 HPLC (Agilent Technologies, Palo Alto, CA, USA) with a Q TRAP™ 3200 
hybrid triple quadrupole linear ion trap mass spectrometer from Applied Biosystems / 
MDS Sciex (Concord, Ontario, Canada). Chromatographic separations were 
accomplished on a Agilent hypersil ODS column (100 ×2.1 mm, 5 μm) (Agilent 
Technologies, Palo Alto, CA, USA) with a guard cartridge. The injection volume and 
column temperature were 5 µl and 25 oC, respectively. The mobile phases consisted of 
0.1 % formic acid in water (solvent A) and acetonitrile (solvent B). The gradient 
elution was set at a flow rate of 0.3 mL/min. The optimized linear gradient elution 
conditions were: 1 % to 95 % B over 40 min, followed by an isocratic hold at 95 % B 
for another 5 min. At 45 min, B was returned to 5 % in 1 min and the column was 
equilibrated for 14 min before the next injection. The total run time was 60 min. The 
mass spectrometer was operated in the positive ion mode with a TurboIonSpray 
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source. A list of 33 MRM transitions with the addition of parent drug in Table 5-2 was 
used to cover the most common phase I and phase II biotransformation reactions of 
meisoindigo. The Q1, Q3, declustering potential (DP), and collision energy (CE) 
values were based on the phase I and II biotransformation prediction of meisoindigo 
by MetaboliteID 1.4 software from Applied Biosystems / MDS Sciex as well as the 
previous results of meisoindigo and its phase I metabolites in rat liver microsomes in 
Chapter 2. The other ionization parameters were as follows: curtain gas (CUR), 20 
(arbitrary units); ion source gas 1 (GS1), 40 (arbitrary units); ion source gas 2 (GS2), 
50 (arbitrary units); source temperature (TEM), 600 ℃; entrance potential (EP), 10 V. 
The dwell time of each MRM transition was 50 msec. The HPLC system and the mass 























TABLE 5-2. MRM transition parameters for meisoindigo and its excretory 













Parent 0 277.1 218.1 66 45 
Hydrogenation 2 279.1 147.1 61 30 
Hydrogenation + demethylation -12 265.1 133.1 60 30 
295.1 163.1 60 30 Hydrogenation + oxidation 18 295.1 147.1 60 30 
Oxidation 16 293.1 249.1 60 40 
Dioxidation 32 309.1 265.1 60 40 
Demethylation -14 263.1 235.1 60 40 
Hydrogenation + dioxidation 34 311.1 178.1 60 30 
471.1 295.1 60 30 
471.1 163.1 60 30 Hydrogenation + oxidation + glucuronidation 194 471.1 147.1 60 30 
375.1 295.1 60 30 
375.1 163.1 60 30 Hydrogenation + oxidation + sulfation 98 375.1 147.1 60 30 
309.1 295.1 60 30 
309.1 163.1 60 30 Hydrogenation + oxidation + methylation 32 309.1 147.1 60 30 
323.1 295.1 60 30 
323.1 163.1 60 30 Hydrogenation + oxidation + dimethylation 46 323.1 147.1 60 30 
600.1 295.1 60 30 
600.1 163.1 60 30 Hydrogenation + oxidation + GSH 323 600.1 147.1 60 30 
457.1 295.1 60 30 
457.1 163.1 60 30 Hydrogenation + oxidation + glucose 180 457.1 147.1 60 30 
Oxidation + glucuronidation 192 469.1 293.1 60 30 
Oxidation + sulfation 96 373.1 293.1 60 30 
Oxidation + methylation 30 307.1 293.1 60 30 
Oxidation + dimethylation 44 321.1 293.1 60 30 
Oxidation + GSH 321 598.1 293.1 60 30 
Oxidation + glucose 178 455.1 293.1 60 30 
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5.3 RESULTS AND DISCUSSION 
5.3.1 Circulatory metabolites in rat plasma 
The extracted ion chromatograms (XIC) of EMS at m/z 277 of the predose and 
postdose samples at different time points in the male rat plasma showed that the peaks 
of meisoindigo were present in the postdose samples while absent in the predose 
sample, indicating no interference from plasma matrix on the detection of 
meisoindigo. The plasma sample collected at 4 h postdose was selected for circulatory 
metabolite identification due to the highest peak abundance of meisoindigo. 
Comparison of EMS for both the plasma predose and postdose samples ranging from 
the retention time of 3 min to 28 min showed two potential metabolites at m/z 279 
which existed in the postdose sample instead of the predose sample and were eluted 
with shorter retention times as compared to that of meisoindigo. Fig. 5-1 showed the 
reconstructed extracted ion chromatograms (XIC) of EMS at m/z 279 and 277 for the 
rat plasma sample at 4 h postdose. This result clearly illustrated two peaks with 
retention times of 17.80 and 20.24 minutes only in the plasma postdose sample rather 
than the predose sample, suggesting that they were potential circulatory metabolites of 
meisoindigo. 
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FIG. 5-1. Reconstructed extracted ion chromatogram (XIC) for meisoindigo and its 
circulatory metabolites in rat plasma at 4 h postdose. 
 
Both of the subsequent EPI (MS/MS) mass spectra of the two potential metabolites at 
m/z 279 in rat plasma at 4 h postdose were identical, indicating these two metabolites 
could be stereoisomers. When compared with the MS/MS spectrum of meisoindigo, 
the fragmentation patterns were similar after calculating the m/z difference between 
each product ion and the molecular ion, which further confirmed that these two peaks 
were structurally related to meisoindigo and should be metabolites of meisoindigo.  
Comparison of the retention times of these two potential circulatory metabolites with 
the two in vitro reductive metabolites in male rat liver microsomes in Chapter 2 
showed that they could be the same compounds. Besides, these two potential 
circulatory metabolites showed the same EPI (MS/MS) mass spectra as those of two 
in vitro reductive metabolites in male rat liver microsomes in Chapter 2. 
Therefore, based on the results from metabolism of meisoindigo in male rat liver 
microsomes in Chapter 2, circulatory metabolites in rat plasma at 4 h postdose were 
 121
M1+M2, a pair of (3-R, 3’-R) and (3-S, 3’-S) reduced-meisoindigo enantiomers with 
two hydrogens located at the same side of 3,3’-single bond, as well as M3+M4, 
another pair of (3-R, 3’-S) and (3-S, 3’-R) enantiomers with two hydrogens located at 
the opposite sides. Furthermore, the different abundance of M1+M2 and M3+M4 
shown in Fig. 5-1 suggested that the reductive metabolism of meisoindigo in rat 
plasma was stereoselective. 
On the other hand, the results of MRM scan showed that significant circulatory 
metabolites in rat plasma were searched out with four MRM transitions i.e. 
279.1→147.1 for hydrogenation, 265.1→133.1 for hydrogenation followed by 
demethylation (Fig. 5-2), 295.1→163.1 and 295.1→147.1 for hydrogenation followed 
by oxidation (Fig. 5-3), respectively. In addition to two reductive metabolite isomers 
described above, two reductive plus N-demethyl metabolite isomers with retention 
times of 18.27 min and 19.61 min were found in rat plasma (Fig. 5-2). Four reductive 
plus phenyl mono-oxidative (at positions 4, 5, 6 or 7) metabolite isomers, and four 
reductive plus phenyl mono-oxidative (at positions 4’, 5’, 6’ or 7’) metabolite isomers 
were observed in rat plasma (Fig. 5-3). Comparison of the retention times of these 
three types of circulatory metabolites with the corresponding in vitro metabolites in 
male rat liver microsomes further showed a good correlation between in vivo 
metabolism in plasma and in vitro metabolism in liver micrsomes. However, in vivo 
metabolism of meisoindigo in rat plasma was less extensive than in vitro metabolism 
of meisoindigo in rat liver micrsomes in terms of the number and intensity of 
metabolites. No novel metabolites were formed in plasma, which were not produced 
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by liver microsomes. Furthermore, the same metabolites were produced in plasma 
with peak intensities generally lower than those from liver microsomes. 
 























FIG. 5-2. Extracted ion chromatogram (XIC) of MRM transition 265.1→133.1 for 
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FIG. 5-3. Extracted ion chromatograms (XIC) of MRM transitions 295.1→163.1 and 
295.1→147.1 for circulatory metabolites of meisoindigo in rat plasma at 4 h postdose. 
 
Based on the metabolite profiling, the major metabolic pathway of meisoindigo in the 
male rat plasma was proposed as 3,3’ double bond reduction, whereas the minor 
metabolic pathways were proposed as reduction followed by N-demethylation, and 
reduction followed by phenyl mono-oxidation (Fig. 5-12). These metabolic pathways 
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were basically consistent with those metabolic pathways in male rat liver microsomes 
reported in Chapters 2 and 3.  
5.3.2 Excretory metabolites in rat urine 
The extracted ion chromatograms (XIC) of EMS at m/z 277 of the predose and 
postdose samples at different time points in the male rat urine showed that the peaks 
of meisoindigo were present in the postdose samples while absent in the predose 
sample, indicating no interference from urine matrix on the detection of meisoindigo. 
The urine sample collected from 0 to 24 h postdose was selected for excretory 
metabolite identification due to its most comprehensive metabolic profile of 
meisoindigo.  
Comparison of XIC for both the urine predose and postdose samples ranging from the 
retention time of 0 min to 38 min showed four potential metabolites at m/z 295 which 
existed in the postdose sample instead of the predose sample and were eluted with 
shorter retention times as compared to that of meisoindigo. Fig. 5-4 showed the 
extracted ion chromatograms (XIC) of EMS from m/z 295 to 295.5 for the rat urine 
sample from 0 to 24 h postdose. This result clearly illustrated four peaks with 
retention times of 32.06, 32.70, 33.16 and 35.64 minutes only in the urine postdose 
sample rather than the predose sample, suggesting that they were potential excretory 
metabolites of meisoindigo. 
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FIG. 5-4. Extracted ion chromatogram (XIC) of EMS from m/z 295 to 295.5 for the 
excretory metabolites of meisoindigo in rat urine collected from 0 to 24 h postdose. 
 
The subsequent EPI (MS/MS) mass spectra of the four potential excretory metabolites 
at m/z 295 showed that there were two types of EPI mass spectra in Fig. 5-5. One type 
was the identical EPI of metabolites with retention times of 32.06 min and 32.70 min, 
indicating these two metabolites should be stereoisomers. The other type was the 
identical EPI of metabolites with retention times of 33.16 min and 35.64 min, 
indicating these two metabolites should also be stereoisomers.  
Comparison of the retention times of these four potential excretory metabolites with 
the in vitro reductive plus mono-oxidative metabolites in male rat liver microsomes in 
Chapter 2 showed that they could be the same compounds. It should be also noted that, 
due to similar chromatographic behaviors of reductive plus mono-oxidative 
metabolite isomers, it was possible that the most abundant peak in Fig. 5-4 comprised 
more than one component showing the same m/z. Besides, these two types of potential 
excretory metabolites showed the same EPI (MS/MS) mass spectra as those of two 
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types of in vitro reductive plus mono-oxidative metabolites in male rat liver 
microsomes in Chapter 2. 
As discussed in Chapter 2, reduction followed by phenyl single oxidation led to two 
different types of position isomers. Considering the generation of two chiral carbon 
centers located in position 3 and 3’, the first type could involve (3-R, 3’-R), (3-S, 
3’-S), (3-R, 3’-S), (3-S, 3’-R), with single hydroxyl group at position 4, 5, 6 or 7. The 
second type could involve (3-R, 3’-R), (3-S, 3’-S), (3-R, 3’-S), (3-S, 3’-R), with 
single hydroxyl group at position 4’, 5’, 6’ or 7’. For each stereoisomer, there were 
four maximal possibilities regarding the specific positions of hydroxyl group on the 
phenyl ring. 
Therefore, based on the results from metabolism of meisoindigo in male rat liver 
microsomes in Chapter 2, excretory metabolites in rat urine from 0 to 24 h postdose 
were (3-R, 3’-R), (3-S, 3’-S), (3-R, 3’-S), (3-S, 3’-R) 
monohydroxyl-reduced-meisoindigo isomers with single hydroxyl group located at 
position 4, 5, 6 or 7, as well as (3-R, 3’-R), (3-S, 3’-S), (3-R, 3’-S), (3-S, 3’-R) 
monohydroxyl-reduced-meisoindigo isomers with single hydroxyl group located at 
position 4’, 5’, 6’ or 7’. Furthermore, the different abundance of excretory metabolites 
shown in Fig. 5-4 suggested that the reduction followed by mono-oxidation 
metabolism of meisoindigo in rat urine was regioselective. 
 
 127
 +EPI (295.00) CE (30): 35.473 to 35.760 min from Sample 1 (EPI-1-295-24h) of EPI-1-295-24h.wiff (Turbo Spray) Max. 2.0e4 cps.






147.2 157.1 267.1130.084.0 277.1116.0 251.2164.0 239.0110.9 174.1 222.1214.1193.192.974.0
 +EPI (295.00) CE (30): 32.974 to 33.228 min from Sample 1 (EPI-1-295-24h) of EPI-1-295-24h.wiff (Turbo Spray) Max. 1.8e5 cps.






267.1133.0 277.184.1 130.1 148.2 164.0 251.1239.1102.1 235.1224.2106.0 193.2167.286.969.0 202.0177.1 296.6
 +EPI (295.00) CE (30): 32.511 to 32.688 min from Sample 1 (EPI-1-295-24h) of EPI-1-295-24h.wiff (Turbo Spray) Max. 4.0e4 cps.







157.1 277.1130.0 193.384.1 263.3239.2134.1 224.2102.1 111.0 162.1 206.0185.268.8 93.1
 +EPI (295.00) CE (30): 31.865 to 32.143 min from Sample 1 (EPI-1-295-24h) of EPI-1-295-24h.wiff (Turbo Spray) Max. 5.6e4 cps.








158.2 277.1263.2193.2130.1 239.2235.1115.1 222.2111.1 162.268.8 203.2181.1 296.491.087.1
 
FIG. 5-5. EPI mass spectra of protonated excretory metabolites of meisoindigo at m/z 
295 in rat urine collected from 0 to 24 h postdose. 
 
Comparison of XIC for both the urine predose and postdose samples ranging from the 
retention time of 0 min to 28 min showed six potential metabolites at m/z 471 and one 
potential metabolite at m/z 375 which existed in the postdose sample instead of the 
predose sample and were eluted with much shorter retention times as compared to that 
of meisoindigo. Fig. 5-6 showed the reconstructed extracted ion chromatograms (XIC) 
of EMS at m/z 471 and 375 for the rat urine sample from 0 to 24 h postdose. This 
result clearly illustrated seven peaks with retention times of 15.90, 18.79, 19.74, 20.25, 
24.26, 25.01 and 27.14 minutes only in the urine postdose sample rather than the 
predose sample, suggesting that they were potential excretory metabolites of 
meisoindigo.  
The metabolites at m/z 471 showed 176 Da increase of molecular weight compared 
with excretory metabolites at m/z 295, suggesting they could be glucuronide 
conjugates of metabolites at m/z 295. The six peaks at m/z 471 could result from 
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isomerization of metabolites at m/z 295 or the acyl-rearrangement of the glucuronide 
conjugate. The subsequent EPI spectra at m/z 471 were not able to be obtained due to 
trace amount of these minor metabolites.  
The metabolites at m/z 375 showed 80 Da increase of molecular weight compared 
with excretory metabolites at m/z 295, suggesting they could be sulfate conjugates of 
metabolites at m/z 295. The EPI spectra at m/z 375 showed the most abundant 
fragment ion at m/z 295 with a loss of 80 Da, thus confirming the occurrence of 
sulfate conjugation. 
 




























FIG. 5-6. Reconstructed extracted ion chromatogram (XIC) for excretory metabolites 
of meisoindigo at m/z 471 and 375 in rat urine collected from 0 to 24 h postdose. 
 
On the other hand, the results of MRM scan showed that significant excretory 
metabolites in rat urine were searched out with thirteen MRM transitions, i.e. 
279.1→147.1 for hydrogenation, 265.1→133.1 for hydrogenation followed by 
demethylation, 295.1→163.1 and 295.1→147.1 for hydrogenation followed by 
oxidation (Fig. 5-7), 293.1→249.1 and 309.1→265.1 for oxidation and dioxidation 
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respectively (Fig. 5-8), 263.1→235.1 for demethylation, 471.1→295.1, 163.1 and 
147.1 for hydrogenation followed by oxidation and subsequent glucuronidation, 
375.1→295.1 for hydrogenation followed by oxidation and subsequent sulfation, 
469.1→293.1 and 373.1→293.1 for oxidation followed by glucuronidation and 
sulfation respectively (Fig. 5-9).  
In terms of phase I excretory metabolites in rat urine, two reductive metabolite 
isomers, two reductive plus N-demethyl metabolite isomers, one N-demethyl 
metabolite were consistent with those found in rat liver microsomes, indicating the 
correlation between in vivo phase I metabolism in urine and in vitro phase I 
metabolism in liver micrsomes. However, reductive plus phenyl mono-oxidative (at 
positions 4, 5, 6 or 7) metabolite isomers, reductive plus phenyl mono-oxidative (at 
positions 4’, 5’, 6’ or 7’) metabolite isomers, and phenyl mono-oxidative (either at 
positions 4, 5, 6, 7 or 4’, 5’, 6’ 7’) metabolite isomers in rat urine showed more 
comprehensive profiles than those found in rat liver microsome according to the 
number and intensity of metabolites (Fig. 5-7 and 5-8), suggesting the more extensive 
oxidation metabolism in vivo. Besides, phenyl di-oxidative (either at positions 4, 5, 6, 
7 or 4’, 5’, 6’ 7’) metabolite isomers were only observed in rat urine rather than rat 
liver microsomes (Fig. 5-8). 
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FIG. 5-7. Extracted ion chromatograms (XIC) of MRM transitions 295.1→163.1 and 
295.1→147.1 for excretory metabolites of meisoindigo in rat urine collected from 0 to 
24 h postdose. 
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FIG. 5-8. Extracted ion chromatograms (XIC) of MRM transitions 293.1→249.1 and 
309.1→265.1 for excretory metabolites of meisoindigo in rat urine collected from 0 to 
24 h postdose. 
 
In terms of phase II excretory metabolites in rat urine, glucuronide and sulfate 
conjugates of both two types of oxidative metabolites at m/z 293 and 295 were 
observed in rat urine. The glucuronide and sulfate conjugations of metabolites at m/z 
295 (Fig. 5-6) were much more significant than those of metabolites at m/z 293 (Fig. 
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5-9) with regard to the number and intensity of metabolites, suggesting hydrogenation 
followed by oxidation was the dominant oxidation metabolism compared with direct 
oxidation. From this point of view, it exhibited the same metabolic trend as that found 
in rat liver microsomes. 
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FIG. 5-9. Extracted ion chromatograms (XIC) of MRM transitions 469.1→293.1 and 
373.1→293.1 for excretory metabolites of meisoindigo in rat urine collected from 0 to 
24 h postdose. 
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 Based on the metabolite profiling above, the major metabolic pathways of 
meisoindigo in male rat urine were proposed as reduction followed by phenyl 
mono-oxidation, as well as its glucuronide conjugation and sulfate conjugation (Fig. 
5-12). The minor metabolic pathways were proposed as direct reduction, direct 
N-demethylation, reduction followed by N-demethylation, direct phenyl 
mono-oxidation and its glucuronide conjugation and sulfate conjugation, direct phenyl 
dioxidation (Fig. 5-12). The phase I metabolic pathways in male rat urine were 
partially consistent with those metabolic pathways in male rat liver microsomes 
reported in Chapters 2 and 3.  
5.3.3 Excretory metabolites in rat feces 
The extracted ion chromatograms (XIC) of EMS at m/z 277 of the predose and 
postdose samples at different time points in the male rat feces showed that the peaks 
of meisoindigo were absent in both of the predose and postdose samples. The feces 
sample collected from 0 to 48 h postdose was selected for excretory metabolite 
identification due to its most comprehensive metabolic profile of meisoindigo.  
Comparison of XIC for both of the feces predose and postdose samples ranging from 
the retention time of 3 to 22 min showed four potential metabolites at m/z 295 which 
existed in the postdose sample instead of the predose sample. Fig. 5-10 showed the 
extracted ion chromatograms (XIC) of EMS from m/z 295 to 295.5 for the rat feces 
sample from 0 to 48 h postdose. This result clearly illustrated four peaks with 
retention times of 13.29, 14.23, 14.87 and 18.70 minutes only in the feces postdose 
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sample rather than the predose sample, suggesting that they were potential excretory 
metabolites of meisoindigo.  
 





























FIG. 5-10. Extracted ion chromatogram (XIC) of EMS from m/z 295 to 295.5 for the 
excretory metabolites of meisoindigo in rat feces collected from 0 to 48 h postdose. 
 
The subsequent EPI (MS/MS) mass spectra of the four potential excretory metabolites 
at m/z 295 showed that there were two types of EPI mass spectra, which were almost 
the same as those shown in Fig. 5-5. One type was the identical EPI of metabolites 
with retention times of 13.29 min and 14.23 min, indicating these two metabolites 
should be stereoisomers. The other type was the identical EPI of metabolites with 
retention times of 14.87 min and 18.70 min, indicating these two metabolites should 
also be stereoisomers.  
Comparison of the retention times of these four potential excretory metabolites with 
the in vitro reductive plus mono-oxidative metabolites in male rat liver microsomes in 
Chapter 2 showed that they could be the same compounds. It should be also noted that, 
due to similar chromatographic behaviors of reductive plus mono-oxidative 
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metabolite isomers, it was possible that the most abundant peak in Fig. 5-10 
comprised more than one component showing the same m/z. Besides, these two types 
of potential excretory metabolites showed the same EPI (MS/MS) mass spectra as 
those of two types of in vitro reductive plus mono-oxidative metabolites in male rat 
liver microsomes in Chapter 2. 
Therefore, based on the results from metabolism of meisoindigo in male rat liver 
microsomes in Chapter 2, excretory metabolites in rat feces from 0 to 48 h postdose 
were (3-R, 3’-R), (3-S, 3’-S), (3-R, 3’-S), (3-S, 3’-R) 
monohydroxyl-reduced-meisoindigo isomers with single hydroxyl group located at 
position 4, 5, 6 or 7, as well as (3-R, 3’-R), (3-S, 3’-S), (3-R, 3’-S), (3-S, 3’-R) 
monohydroxyl-reduced-meisoindigo isomers with single hydroxyl group located at 
position 4’, 5’, 6’ or 7’. Furthermore, the different abundance of excretory metabolites 
shown in Fig. 5-10 suggested that the reduction followed by mono-oxidation 
metabolism of meisoindigo in rat feces was regioselective. 
On the other hand, the results of MRM scan showed that significant excretory 
metabolites in rat feces were searched out with four MRM transitions, i.e. 
265.1→133.1 for hydrogenation followed by demethylation, 295.1→163.1 and 
295.1→147.1 for hydrogenation followed by oxidation, 311.1→178.1 for 
hydrogenation followed by dioxidation (Fig. 5-11).  
In terms of excretory metabolites in rat feces, reductive plus N-demethyl metabolite 
isomers, reductive plus phenyl mono-oxidative (at positions 4, 5, 6 or 7) metabolite 
isomers, reductive plus phenyl mono-oxidative (at positions 4’, 5’, 6’ or 7’) 
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metabolite isomers were consistent with those found in rat liver microsomes, 
indicating the correlation between in vivo phase I metabolism in rat feces and in vitro 
phase I metabolism in rat liver micrsomes. However, reductive plus phenyl 
di-oxidative metabolite isomers were only observed in rat feces rather than rat liver 
microsomes (Fig. 5-11), suggesting the more extensive oxidation metabolism in vivo. 
 





























FIG. 5-11. Extracted ion chromatogram (XIC) of MRM transition 311.1→178.1 for 
excretory metabolites of meisoindigo in rat feces collected from 0 to 48 h postdose. 
 
Based on the metabolite profiling above, the major metabolic pathway of meisoindigo 
in the male rat feces was proposed as reduction followed by phenyl mono-oxidation, 
whereas the minor metabolic pathways were proposed as reduction followed by 
N-demethylation, and reduction followed by phenyl di-oxidation (Fig. 5-12). These 
metabolic pathways were partially consistent with those metabolic pathways in male 








































































































































































































FIG. 5-12. Proposed metabolic pathway of meisoindigo in male rat plasma, urine and 
feces. Chiral centers are indicated with asterisks. 
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CHAPTER 6 
Conclusions 
                                                                      
This thesis investigated the in vitro phase I interspecies metabolism of meisoindigo in 
rat, pig and human liver microsomes, as well as in vivo phase I and II metabolism of 
meisoindigo in rat plasma, urine and feces by LC-MS/MS. Furthermore, in vitro phase 
I metabolism of meisoindigo in rat kidney microsomes and gender effects on the in 
vitro metabolism were also studied by LC-MS/MS. The main findings of this thesis 
involved metabolite detection and structural elucidation, as well as parent drug and 
metabolites quantification, in both qualitative and quantitative aspects as follows. 
In Chapter 2, in vitro stereoisomeric metabolites of meisoindigo in male rat liver 
microsomes were identified by achiral and chiral liquid chromatography / tandem 
mass spectrometry, together with proton NMR spectroscopy and synchrotron infrared 
spectroscopy. The major in vitro phase I metabolites of meisoindigo were tentatively 
identified as stereoselective reduced-meisoindigo, which comprised a pair of (3-R, 
3’-R) and (3-S, 3’-S) enantiomers with lower abundance, as well as another pair of 
(3-R, 3’-S) and (3-S, 3’-R) enantiomers with higher abundance. One type of minor in 
vitro metabolites were tentatively identified as stereoselective 
N-demethyl-reduced-meisoindigo including a pair of (3-R, 3’-R) and (3-S, 3’-S) 
enantiomers, as well as one meso compound. Another type of minor in vitro 
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metabolites were tentatively identified as both stereoselective and regioselective 
monohydroxyl-reduced-meisoindigos. Based on the metabolite profiling, three 
parallel metabolic pathways of meisoindigo in rat liver microsomes were proposed.  
In Chapter 3, the relevant metabolism studies were carried out in rat, pig and human 
liver microsomes of different genders by ultra fast liquid chromatography / tandem 
mass spectrometry (UFLC-MS/MS). The qualitative metabolite identification was 
accomplished by multiple reaction monitoring (MRM) in combination with Enhanced 
Product Ion (EPI). The semi-quantitative metabolic stability and metabolite formation 
were simultaneously measured by MRM. The in vitro metabolic pathways of 
meisoindigo in three species were proposed as 3,3’ double bond reduction, reduction 
followed by N-demethylation, and reduction followed by phenyl mono-oxidation. 
Two more novel metabolic pathways were proposed as direct phenyl mono-oxidation 
in three species, as well as direct N-demethylation in only pig and human. In 
particular, two metabolites undergone reduction followed by phenyl mono-oxidation 
at positions 4, 5, 6 or 7, as well as one metabolite undergone direct phenyl 
mono-oxidation were found to be uniquely present in human, which implied a proper 
attention to the correlation between human and these two preclinical animal species. 
The in vitro t1/2 and in vitro CLint values of meisoindigo were calculated. Statistical 
analysis showed there were no significant differences in the metabolic stability 
profiles of meisoindigo among three species, and gender effect on the metabolic 
stability of meisoindigo was negligible. Formation profiles of the most significant 
reductive metabolites were obtained in the three species. 
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In Chapter 4, the metabolism of meisoindigo in rat kidney microsomes was 
qualitatively and quantitatively investigated by LC-MS/MS, in terms of metabolite 
identification, metabolic stability, metabolite formation and gender effect. The 
metabolic profiling was accomplished by integration of MRM with conventional full 
MS scan followed by MS/MS methodology. The major in vitro metabolites of 
meisoindigo in rat kidney microsomes were identified as stereoselective 3,3’ double 
bond reduced-meisoindigo, whereas the minor metabolites were regioselective phenyl 
monohydroxyl-meisoindigo. The in vitro half-life (t1/2) values of meisoindigo in male 
and female rat kidney microsomes were calculated, respectively. There were no 
statistically significant differences between different genders in the metabolic stability 
profiles of meisoindigo. The reductive metabolite-formation profiles of meisoindigo 
in male and female rat kidney microsomes were plotted semi-quantitatively as well. 
Compared with the metabolic profile of meisoindigo in rat liver microsomes, the 
types of metabolites produced in rat kidney microsomes were much less and their 
quantities were much lower, indicating that liver is the major metabolizing site for 
meisoindigo.  
In Chapter 5, the in vivo circulatory metabolites of meisoindigo in male rat plasma, as 
well as in vivo excretory metabolites of meisoindigo in male rat urine and feces were 
identified by LC-MS/MS qualitatively. Integration of MRM with conventional 
metabolic profiling methodology enabled a more sensitive detection of in vivo 
metabolites. The major metabolic pathway in the rat plasma was proposed as 3,3’ 
double bond reduction, whereas the minor metabolic pathways were proposed as 
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reduction followed by N-demethylation, and reduction followed by phenyl 
mono-oxidation. The major metabolic pathways in the rat urine were proposed as 
reduction followed by phenyl mono-oxidation, as well as its glucuronide conjugation 
and sulfate conjugation, whereas the minor metabolic pathways were proposed as 
direct reduction, direct N-demethylation, reduction followed by N-demethylation, 
direct phenyl mono-oxidation and its glucuronide conjugation and sulfate conjugation, 
direct phenyl dioxidation. The major metabolic pathway in the rat feces was proposed 
as reduction followed by phenyl mono-oxidation, whereas the minor metabolic 
pathways were proposed as reduction followed by N-demethylation, and reduction 
followed by phenyl di-oxidation. The phase I metabolic pathways showed a 
significant in vitro-in vivo correlation in rat.  
This thesis has investigated for the first time the meisoindigo metabolism by the most 
sensitive technique LC-MS/MS, though meisoindigo has been applied for clinical 
treatment for many years. The correlation in the in vitro metabolism of meisoindigo in 
human and the two preclinical animal species, i.e. rat and pig, provides adequate 
evidence for the prediction of in vitro metabolism of meisoindigo in human from in 
vitro metabolism of meisoindigo in rat or pig. It should be also noted that the unique 
metabolites which are only present in human rather than other preclinical animal 
species must be seriously taken into account in the process of the human metabolism 
prediction using other species. In addition, the in vitro-in vivo phase I metabolism 
correlation of meisoindigo in rat proves the validity of making a prediction of in vivo 
metabolic pathways from in vitro metabolic pathways in liver microsomes, despite the 
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fact that the in vivo metabolism is subject to numerous influences and thus much more 
complicated than in vitro metabolism. In terms of clinical application, the overall 
results bring about the improvement in the understanding about the safety and 
efficiency characteristics of meisoindigo for chronic myelogenous leukemia treatment, 
especially about the metabolic profile of meisoindigo in humans, as well as the role of 
the kidney in the disposition of meisoindigo for chronic myelogenous leukemia 
treatment. Based on these results, adjustment can be made to the dosage regimens, 
such as daily dose, administration frequency and duration, to achieve the maximal 
efficiency and minimal adverse effects. The renal metabolism of meisoindigo should 
be taken into account as well in the determination of optimum drug therapy, 
particularly for patients with renal impairment.  
As it is the first time to investigate the metabolic profile of meisoindigo, the content 
covered in this thesis is not comprehensive and more studies need to be carried out in 
the following aspects.  
(1) The activities of primary in vitro and in vivo metabolites of meisoindigo were not 
determined. Considering the hydrophilic metabolites generally show a better 
solubility than their respective parent drugs, the structures of metabolites could be 
further modified to search for new lead compounds with higher or even comparable 
activity than the parent drugs, as long as these new compounds show better 
physicochemical properties to facilitate their oral absorption and improve their 
bioavailability.  
(2) The reactive metabolites of meisoindigo generated in the in vitro models were not 
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investigated to further predict the actual toxicity situation in human body. But 
according to literature review, meisoindigo generally showed mild side effects in 
chronic myelogenous leukemia patients (Liu et al., 2000). Further work could be done 
to investigate the cause of these mild side effects by extrapolation from in vitro 
reactive metabolites, or by direct toxicity determination of synthetic in vivo 
metabolites. In particular, for the in vitro metabolites uniquely present in human liver 
microsomes while absent in rat or pig liver microsome, some consideration should be 
given to evaluate whether the metabolite poses an unidentified risk to human safety. 
(3) The in vitro model used in this thesis was only limited to microsomes, which have 
to rely on the key external factors triggering the biotransformation reactions and do 
not accurately mimic the actual physiological environment in the body. Hepatocyte is 
the best in vitro model at present for drug metabolism study, since it contains almost 
all of the necessary physiological ingredients and approximately mimics the real in 
vivo situation without any external factors being added. Thus the hepatocyte could be 
used to further validate the present results in this thesis. 
(4) Considering meisoindigo was clinically administered in combination with other 
anti-leukemic agents especially hydroxyurea (Xiao et al., 2000), the inhibition and 
induction assays of meisoindigo by cytochrome P450 could be carried out to identify 
the isoforms involved in the meisoindigo metabolism and further predict the potential 
drug-drug interactions based on the reported isoforms of other anti-leukemic agents.  
(5) Since the mechanism of action of meisoindigo in the treatment of chronic 
myelogenous leukemia has not been well understood so far (Xiao et al., 2000), more 
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work could be performed to investigate it from the point of view of molecular 
pharmacology. A new in vitro model could be also developed to explore the synergetic 
mechanism of meisoindigo and other anti-leukemic agents. 
(6) Routine pharmacokinetic parameters such as oral bioavailability, plasma half-life, 
clearance and area under the “plasma concentration versus time” curve (AUC) could 
be determined from plasma in rats following oral administration of meisoindigo. 
These results could be compared with those of rat, pig and human-based in vitro 
assays to investigate the correlation between in vitro and in vivo assays and species 
differences. If one metabolite is active or substantially exceeds the parent drug in 
terms of concentration and/or activity, it is imperative to elucidate the 
pharmacokinetics of the metabolite in order to understand and predict expected 
changes in active metabolite concentration and/or activity (Jackson et al., 2000). This 
is especially important when the parent drug is administered on a long-term basis such 
as meisoindigo. 
(7) Depending on the particular drug involved, extrahepatic organs and/or tissues such 
as lung and colon etc may account for a significant part of metabolic clearance of the 
drug (De Kanter et al., 2004). Prospective studies involving the extrahepatic 
metabolism of meisoindigo in the lung and colon could be considered to provide a 
more comprehensive metabolic profile of this drug. 
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APPENDIX 1. UPLC-QTOF RESULTS FOR MEISOINDIGO AND ITS IN 








Appendix 1-1. Base Peak Intensity (BPI) and extracted ion chromatogram (XIC) of 







Appendix 1-2. Base Peak Intensity (BPI) and extracted ion chromatogram (XIC) of 









Appendix 1-3. Base Peak Intensity (BPI) and extracted ion chromatogram (XIC) of 















Appendix 1-4. Base Peak Intensity (BPI) and extracted ion chromatogram (XIC) of 







APPENDIX 2. MS/MS/MS (MS3) RESULTS FOR MEISOINDIGO AND ITS IN 
VITRO METABOLITES 
 +MS3 (277.10),(218.10): 32 MCA scans from Sample 1 (MS3-218-CE-47-AF2-40) of MS3-218-CE-47-AF2-40.wiff (Turbo Spray) Max. 1.0e6 cps.



























Appendix 2-1. MS3 spectrum of the product ion at m/z 218 generated from protonated 
meisoindigo at m/z 277. 
 +MS3 (277.10),(234.20): 32 MCA scans from Sample 1 (MS3-234-CE-45-AF2-45) of MS3-234-CE-45-AF2-45.wiff (Turbo Spray) Max. 1.5e7 cps.







































178.3 191.2 235.7165.1 210.1 217.2204.0152.2146.0 238.2
 
Appendix 2-2. MS3 spectrum of the product ion at m/z 234 generated from protonated 
meisoindigo at m/z 277. 
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  +MS3 (279.10),(147.10): 32 MCA scans from Sample 1 (MS3-147-CE-41-AF2-25) of MS3-147-CE-41-AF2-25.wiff (Turbo Spray) Max. 3.7e5 cps.


























Appendix 2-3. MS3 spectrum of the product ion at m/z 147 generated from protonated 
metabolites at m/z 279. 
 
 +MS3 (279.10),(251.10): 32 MCA scans from Sample 1 (MS3-251-CE-23-AF2-25) of MS3-251-CE-23-AF2-25.wiff (Turbo Spray) Max. 6.3e5 cps.























Appendix 2-4. MS3 spectrum of the product ion at m/z 251 generated from protonated 
metabolites at m/z 279. 
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APPENDIX 3. HPLC-MS/MS PROFILE OF HYDROGENATION PRODUCTS 












































































Appendix 3-1. Total ion chromatograms (TIC) of EMS for synthetic product and rat 
liver microsomal sample. Diluted hydrogenation products after two hours reaction 
showed the same retention times and fragmentation patterns on LC-MS/MS as the two 





APPENDIX 4. HPLC-MS/MS RESULTS OF FULL SCAN SPECTRA (EMS) 
AND UV CHROMATOGRAMS AT 254 NM FOR THREE MALE SPECIES 
 
TIC of +EMS: from Sample 1 (40-3-S) of 40-3-S.wiff (Turbo Spray) Max. 2.0e8 cps.


















Channel 1 from Sample 1 (40-3-S) of 40-3-S.wiff Max. -24.2 %.


















metabolites Rat UV M279-2 M279-1
 
Appendix 4-1. EMS and UV for male rat liver microsomal samples after incubation 
for 60 min with substrate concentration of 50 uM. 
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TIC of +EMS: from Sample 1 (40-P-S) of 40-P-S.wiff (Turbo Spray) Max. 2.2e8 cps.

















Channel 1 from Sample 1 (40-P-S) of 40-P-S.wiff Max. -14.8 %.

















Appendix 4-2. EMS and UV for male pig liver microsomal samples after incubation 
for 60 min with substrate concentration of 50 uM. 
 
 
TIC of +EMS: from Sample 1 (40-H-S) of 40-H-S.wiff (Turbo Spray) Max. 3.1e8 cps.













Channel 1 from Sample 1 (40-H-S) of 40-H-S.wiff Max. -8.9 %.





















Appendix 4-3. EMS and UV for male human liver microsomal samples after 
incubation for 60 min with substrate concentration of 50 uM. 
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APPENDIX 5. HPLC-MS/MS RESULTS OF CIRCULATORY AND 
EXCRETORY METABOLITES OF MEISOINDIGO IN RAT PLASMA, URINE 
AND FECES 

























Appendix 5-1. Extracted ion chromatogram (XIC) of MRM transition 279.1→147.1 
for circulatory metabolites of meisoindigo in rat plasma at 4 h postdose. 
 
 




















Appendix 5-2. EPI mass spectra of protonated excretory metabolites of meisoindigo at 
m/z 375 in rat urine collected from 0 to 24 h postdose. 
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Appendix 5-3. Extracted ion chromatogram (XIC) of MRM transition 279.1→147.1 






























Appendix 5-4. Extracted ion chromatogram (XIC) of MRM transition 265.1→133.1 




























Appendix 5-5. Extracted ion chromatogram (XIC) of MRM transition 265.1→133.1 
for excretory metabolites of meisoindigo in rat feces collected from 0 to 48 h 
postdose. 
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